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CHAPTER 1 
GENERAL INTRODUCTION 
ACUTE CORONARY SYNDROMES 
The term acute coronary syndromes (ACS) serves as an umbrella to cover clinical symptoms compatible 
with myocardial ischemia, including unstable angina pectoris and acute myocardial infarction (AMI). 
These life-threatening disorders are a major cause of emergency medical care and hospitalization. 
Furthermore, cardiovascular diseases remain the leading cause of death in the Netherlands and Europe. 
In the Netherlands, 136,553 people died in 2004 and cardiovascular diseases were the leading cause of 
death with 45,445 deaths (33%). Second were malignant neoplasms causing 38,824 deaths (28%). 
Within cardiovascular diseases, ACS are the most common cause of death (14,083; 31%), comprised 
mostly of AMI with 10.012 deaths (71%) (Table 1-1).1 
 
Table 1-1. Causes of death due to cardiovascular diseases in the Netherlands in 2004. From Koek et al. 1 
Cause of death Men Women Total 
Acute coronary syndromes 7,966 37% 6,117 26% 14,083 31% 
 - acute myocardial infarction 5,543  4,469  10,012  
Cerebrovascular 4,341 20% 6,784 28% 11,089 24% 
Congenital 84 0.4% 84 0.4% 168 0.4% 
Rheumatic and valvular 567 2.6% 882 3.7% 1,449 3.2% 
Infectious 316 1.5% 396 1.7% 712 1.6% 
Other 5,690 26% 7,147 30% 12,837 28% 
 - heart failure 2,201  3,423  5,624  
Arterial vascular 1,334 6.1% 710 3% 2,044 4.5% 
Atherosclerosis / hypertension 1,049 48% 1,190 5% 2,239 4.9% 
Venous vascular 58 0.3% 95 0.4% 153 0.3% 
Other (circulation / lymph) 291 1.3% 380 1.6% 671 1.5% 
Total 21,696 100% 23,749 100% 45,445 100% 
 
Rapid diagnosis of ACS is of utmost importance, because most deaths occur in the early hours after 
onset of symptoms, and therapeutic interventions should preferably start within the first 6 hours.2 
Clinical evaluation, including anamnesis and electro cardiogram (ECG), combined with laboratory 
analysis of biomarkers of cardiac function, aid the clinician in correctly diagnosing a patient. 
Therapeutic interventions are directed primarily at restoring coronary blood flow (reperfusion). These 
interventions can be either intravenous thrombolytic therapies such as streptokinase, or percutaneous
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coronary intervention (PCI) (Table 1-2).3 Preserving myocardial (left ventricular) function and reducing 
morbidity and mortality are therapeutic goals after the first critical hours have passed. 
In the last two decades, one-year mortality resulting from a primary or secondary AMI has reduced 
from 39% to 25% and from 43% to 29%, respectively.4 However, in patients with prior hospital 
admissions for diabetes, respiratory disease, peripheral vascular disease, cancer or heart failure, the 
relative risk of dying within 30 days was increased by up to twofold.5 
 
Table 1-2. Reperfusion therapy by geographic region. From Eagle et al.3 
 Patients receiving reperfusion therapy 
Therapy ANC (n=269) USA (n=327) AB (n=339) Europe (n=739) 
PCI alone 1.1 17.7 13.9 16.2 
Thrombolysis alone 66.9 30.6 53.1 49.4 
Both 2.2 18.7 5.0 4.9 
Neither 29.7 33.0 28.0 29.5 
ANC=Australia, New Zealand, Canada; AB=Argentina, Brazil. PCI=percutaneous coronary intervention. 
MYOCARDIAL INFARCTION 
There have been several attempts to define AMI (Figure 1-1). In the past, definitions of cases for 
epidemiology studies and clinical trials in ACS were based on World Health Organization (WHO) (1959) 
and American Heart Association (1964) reports, followed by the WHO European AMI Registry criteria.6, 7 
AMI was defined by a combination of two of three characteristics: typical symptoms (i.e., chest 
discomfort), cardiac enzyme rise and a typical ECG pattern involving the development of Q waves.8 
Further specification and working definitions of ACS come from the Framingham Study.9 More recently 
the WHO MONICA Study has modified further the definition of ACS cases.8 
In 2000, the joint European Society of Cardiology and the American College of Cardiology 
recommended a new definition for AMI that combined ischemic symptoms with changes in the ECG and 
in biochemical markers of myocardial necrosis and emphasized the use of cardiac troponins.10, 11 In the 
new definition, cardiac troponins (either cTnT or cTnI) are the biomarker of choice because these have 
been shown to be specific for cardiac tissue and highly sensitive to minor myocardial damage.12-14 
 
The criteria for acute, evolving or recent MI have been defined as: 
1.  A typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical 
markers of myocardial necrosis with at least one of the following: 
a) ischemic symptoms; 
b) development of pathologic Q waves on the ECG; 
c) ECG changes indicative of ischemia (ST segment elevation or depression); or 
d) coronary artery intervention (e.g. coronary angioplasty). 
2.  Pathologic findings of an acute MI. 
 
The criteria for established MI have been defined as: 
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1.  Development of new pathologic Q waves on serial ECGs. The patient may or may not remember 
previous symptoms. Biochemical markers of myocardial necrosis may have normalized, 
depending on the length of time that has passed since the infarct developed. 
2.  Pathologic findings of a healed or healing MI. 
 
In the “old” definition, diagnosis was based on elevations of the creatine kinase MB fraction (CK-MB). 
The new definition has been criticized for excessive reliance on troponins and insufficient attention to 
ECG changes.15, 16 Moreover, there are several important issues regarding the new definition.17, 18 It was 
foreseen that the new definition would substantially increase the number of patients diagnosed with 
AMI.19 Recently, prospective application of the new criteria in the community indeed showed a large 
increase in the number of patients with AMI.20 Many people formerly diagnosed with unstable angina, 
are now diagnosed as having AMI. This has a major impact on epidemiological studies comparing 
studies performed before and after the new definition. Also, studies based on mortality will face 
difficulties, as mortalities will fall.18 
 
Figure 1-1. Terminology of acute coronary syndromes pre and post-“consensus” definition.10, 11 Cardiac troponins are 
elevated earlier than creatine kinase and are more sensitive markers of cardiac injury. UAP, unstable angina pectoris; 
MI, myocardial infarction. Adapted from.21 
Ischemia 
Atherosclerosis is a progressive disease, characterized by the accumulation of lipids, cells and fibrous 
elements in the vessel wall of large and medium-sized arteries.22 Such “plaques” can be either stable, 
or ruptured. Stable plaques have an intact fibrous cap composed of smooth muscle cells and 
extracellular matrix that encloses a lipid-rich necrotic core. Plaques can become increasingly complex, 
with calcification, ulceration at the luminal surface, and haemorrhage from small vessels that grow into 
the lesion from the media of the blood vessel wall (Figure 1-2). 
Obstruction of a blood vessel can be caused by two mechanisms. Firstly, advanced plaques can grow 
sufficiently large to block blood flow. This is a slow process. The occlusion can be up to 70% without 
any clinical symptoms due to adaptive mechanisms of the heart. However, eventually, the heart will 
become transiently ischemic, leading to periods of chest pain. 
Secondly, due to unknown events plaques may be subject to erosion or rupture, thereby exposing their 
contents to the bloodstream. Rupture frequently occurs at the edges of a plaque, which are rich in foam 
cells, suggesting that factors contributing to inflammation may also influence thrombosis. In this 
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regard, it is notable that the incidence of myocardial infarction and stroke increases during acute 
infections.23 The resulting activation of the blood coagulation cascade can lead to thrombus formation.22 
This can cause obstruction of the vessel lumen, leading to downstream ischemia: an acute myocardial 
infarction. 
Reperfusion techniques 
The main treatment goal for a patient who has suffered an AMI is to open the occluded vessel. From a 
historical point of view, pharmacological interventions have been the first option.24 The first 
thrombolytic agents included streptokinase and tissue-type plasminogen activator (t-PA). Limitations of 
the first and second generation agents have resulted in the development of more potent third 
generation thrombolytic agents, which more specifically degrade fibrin, have increased resistance to 
plasma protease inhibitors or have longer half-lives.25 Adjunctive agents include unfractionated heparin, 
low-molecular weight heparin and platelet inhibitors (glycoprotein IIb/IIIa inhibitors). 
 
Figure 1-2. Schematic presentation of a stable atherosclerotic lesion. L, lumen; A, adventitia; I, intima; IEL, internal 
elastic lamina; M, media. 
 
The preferred therapy of today is PCI. This technique involves a fine hollow catheter to be inserted into 
the femoral artery. This catheter, with a small inflatable balloon at its tip, is fed through to the 
narrowed coronary artery. When the balloon is gently inflated, this compresses the atherosclerotic 
plaque -responsible for the narrowing of the vessel-, and widens the lumen of the artery. This is often 
accompanied by inserting a bare metal stent, an expandable wire mesh tube, used to support the new 
stretched open position of the artery from the inside, thereby reducing the risk of re-occlusion or 
restenosis.26 The stents used today, drug-eluting stents, are often coated with drugs that help prevent 
restenosis.27 Importantly, however, recent studies have shown that the risk of restenosis, the 
occurrence of death, reinfarction, or heart failure was not reduced when using drug-eluting stents 
compared with bare metal stents.28, 29 Furthermore, a recent study showed that in patients with stable 
coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major 
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cardiovascular events when added to optimal medical therapy.30 More literature on this topic is slowly 
being published. In extreme cases, when PCI is not sufficient, or when there are several occlusions, 
coronary artery bypass grafting (CABG) is another surgical option. 
CARDIAC MARKERS 
The history of protein markers in diagnosis and treatment of ACS dates back to 1954 with reports on 
aspartate aminotransferase (AST).31, 32 Ever since, this important field has evolved and new and better 
markers have been described aiding clinicians in diagnosis and treatment of ACS. These included the 
enzymes lactate dehydrogenase (LDH),33 α-hydroxybutyrate dehydrogenase (HBDH),34 creatine kinase 
(CK),35, 36 and the protein myoglobin.37 More recently, the more cardiac tissue specific markers CK-
MB,38-41 heart-type fatty acid binding protein (H-FABP),42 brain natriuretic peptide (BNP),43, 44 and the 
cardiac troponins I and T have been introduced as markers of cardiac dysfunction.12, 14 The time course 
of appearance of some of these cardiac markers in the circulation is shown in Figure 1-3. 
 
Figure 1-3.Time course of appearance of cardiac markers in blood after onset of AMI. 
Peak A, early release of myoglobin or CK-MB isoforms after AMI; peak B, cardiac troponin after AMI; peak C, CK-MB after 
AMI; peak D, cardiac troponin after unstable angina. Data are plotted on a relative scale, where 1.0 is set at the AMI cut-
off concentration. Adapted from Wu et al.45 
Creatine kinase and iso-enzymes 
Creatine kinase is a cytosolic enzyme (81 kDa) expressed in various tissue types. The two subunits of 
this dimeric enzyme can either be B-type (brain) or M-type (muscle), yielding three possible iso-
enzymes (MM, BB and MB), which are all present in tissue, but the composition varies. Skeletal muscle 
expresses CK-MM at high levels (99%) and CK-MB at low levels (1.1%), whereas cardiac muscle, in 
contrast, expresses CK-MM at 79% and CK-MB at 20%.46 It is important to realize that the total CK 
activity in skeletal muscle is about 5-10 fold higher than in cardiac muscle, so that in absolute values 
(activity per gram wet weight tissue), skeletal muscle contains approximately equal amounts of CK-
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MB.46 However, because cardiac muscle contains the largest proportion of CK-MB, this was the first 
biochemical marker for AMI that was relatively specific for necrotic myocardium. Depending on the 
analytical method (substrate conversion or immunologically), CK-MB is expressed either as activity in 
U/L (CK-MBact), or as concentration in µg/L (CK-MBmass). 
The function of CK is the conversion of creatine to creatinephosphate, consuming adenosine 
triphosphate (ATP) and generating adenosine diphosphate (ADP), and the reverse reaction (equation 1-
1). 
 
Creatinine + ATP ⎯⎯ →← CK  Creatinine phosphate + ADP (1-1) 
 
Creatinephosphate is the major source of energy in biochemical reactions and serves as an energy 
reservoir for the regeneration of ATP in tissues that consume ATP rapidly (especially striated muscle, 
but also the brain and smooth muscle cells). First, ATP is generated inside the mitochondria of the cell. 
The mitochondrial CK then catalyses the phosphorylation of creatine to creatinephosphate, which is 
then transported to sites of energy need. There CK facilitates the reverse transformation of ADP into 
ATP. 
Throughout the studies presented in this thesis, CK activity is measured on a Synchron LX system 
(Beckman Coulter) by an enzymatic rate method. CK catalyses the transfer of a phosphate group from 
the creatinephosphate substrate to ADP. This formation of ATP is measured through the use of two 
coupled reactions catalyzed by hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH) 
which results in the production of reduced β-nicotinamide adenine dinucleotide (NADH+) from β-
nicotinamide adenine dinucleotide (NAD+) (Equation 1-2). The system measures the change in 
absorbance at 340 nm, which is directly proportional to the activity of CK. 
 
Creatine phosphate + ADP ⎯⎯ →⎯ CK  Cretinine + ATP 
ATP + Glucose ⎯⎯ →⎯ HK  Glucose-6-phosphate + ADP (1-2) 
Glucose-6-phosphate + NAD+ ⎯⎯⎯⎯ →⎯ PDHG6  6-phosphogluconate + NADH+ 
 
To specifically measure the activity of the CK-MB isoform, a monoclonal antibody against the M subunit 
is incubated with the serum sample. This completely blocks CK-MM activity, and 50% of the CK-MB 
activity. Because CK-BB is not normally present in measurable amounts in serum, the measured 
activity is exactly half of the total CK-MB activity. Doubling of the result yields the total activity of CK-
MB. 
Throughout the studies presented in this thesis, the CK-MB concentration (CK-MBmass) is measured on 
the Elecsys 2010 immunoassay system with a sandwich principle. In the first step, serum is combined 
with a reagent mixture containing biotinylated monoclonal anti-CK-MB antibody and a ruthenium-
labelled monoclonal anti-CK-MB antibody. In the second step, streptavidin-coated paramagnetic micro 
particles are added and incubated. The now formed immune complexes are magnetically captured on 
an electrode in a measuring cell and application of a 0.2 mV voltage results in an 
electrochemiluminescent signal. This is calibrated against an internal standard curve, constructed with 
two calibrators. The serum detection limit for the CK-MBmass assay is 0.1 µg/L. Between-day variation is 
3.6% and 5.3% at concentrations of 5.58 µg/L and 53.3 µg/L, respectively (n=75). The reference 
values are <4.9 µg/L for men and <2.9 µg/L for women. 
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TROPONINS 
Immunoassays 
The principal components of the contractile apparatus of striated muscle (sarcomere) are the actin 
based thin filament, the myosin based thick filament, tropomyosin, and the troponin complex (Figure 1-
4). During muscle contraction, the actin and myosin filaments slide over each other. This action is 
energy consuming and requires adenosine triphosphate (ATP) and calcium, which is released from the 
sarcoplasmic reticulum upon calcium influx resulting from depolarization of nerve fibres. 
The troponin complex is comprised of three proteins: troponin T, troponin I and troponin C, and resides 
on the thin filament. Troponin T structurally binds the troponin complex via troponin C to tropomyosin. 
Binding of Ca2+ to troponin C results in conformational changes and increased affinity of troponin C for 
troponin I. Troponin I then releases its inhibitory function on actomyosin ATPase, which leads to ATP 
hydrolysis and muscle contraction.47 
Troponin C is identical in both skeletal and cardiac muscle. Troponin I and T, however, are encoded by 
different genes, yielding two immunologically different proteins.12, 14, 48, 49 Both proteins have specific 
isoforms for skeletal muscle (sTnT, sTnI) and cardiac muscle (cTnT, cTnI). The latter are highly specific 
and highly sensitive biomarkers for detecting minor cardiac damage.12, 14, 50 Hence, cTnI and cTnT are 
now the preferred biomarkers for diagnosis and prognosis of acute coronary syndromes and have 
replaced CK-MBmass.10, 11, 51 
Ever since it became apparent that antibodies against cTnT were able to discriminate between skeletal 
and cardiac isoforms, immunoassays have been developed and improved.53 In 1989 the first generation 
cTnT immunoassay was released. This was a one step ELISA method, which employed polyclonal goat-
anti-human anti-troponin T antibodies, immobilised on polyvinylchloride test tubes and peroxidase 
labelled monoclonal anti-troponin T antibody 1B10 for detection.12 The latter had 12% cross reactivity 
to skeletal muscle troponin T.54, 55 Overall, the assay displayed 1% cross reactivity to skeletal TnT,12 
likely attributable to unspecific binding of skeletal muscle troponin T to the test tube and detection by 
the cross-reactive monoclonal antibody 1B10 used as label.56 The detection limit of this assay was 0.04 
µg/L and the turnaround time was 90 minutes. Some years later, the assay (Enzymun®) was improved 
by replacing the capture antibodies with biotin labelled monoclonal capture antibody M7, without 
significant cross reactivity to skeletal TnT, and antibody 1B10 for detection, combined with streptavidin-
coated tubes as the solid phase to reduce unspecific binding.54 
The second generation, a new and more-specific version of the troponin T ELISA, was developed and 
used a new antibody combination.56 The second generation cTnT immunoassay used two cardiospecific 
monoclonal anti-cTnT antibodies, biotin labelled monoclonal capture antibody M11.7 (recognising amino 
acid residues 136-147) and horseradish peroxidase labelled monoclonal detection antibody M7 
(recognising amino acid residues 125-131). The latter was first used as capture antibody. The detection 
limit of this assay was lower (0.0123 µg/L), the imprecision was lower and the turnaround time was 
reduced to 45 minutes.56, 57 Calibration of the assay was performed with purified bovine cTnT spiked in 
human serum. It was proposed to use a cut-off of 0.1 µg/L for diagnosis of patients with myocardial 
damage.56 
The third generation assay uses recombinant human cTnT as calibration material. The new assay has a 
more linear calibration curve. Thus, linearity problems observed with the second generation assay have 
been eliminated. The assay has high precision, especially at the low end of measuring range.58 The 
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detection limit in serum and heparin plasma is <0.010 µg/L, which is equal to the 99th percentile 
reference limit in healthy volunteers.59, 60 Heparin plasma has, however, been shown to generate 
markedly decreased concentrations compared with serum.61, 62 Speth et al. concluded that the apparent 
decrease in cTnT values in heparin plasma was a result of direct molecular interaction between the 
negatively charged glycosaminoglycan and clusters of basic residues within the cTnT molecule.63 
 
Figure 1-4. Structure of the striated muscle contractile apparatus. A) Structure of a sarcomere with the actin based thin 
filament and the myosin based thick filament. B) Position of tropomyosin and actin when the muscle is relaxed and no 
Ca2+ is bound. C) Position of tropomyosin and actin when muscle is contracting after Ca2+ binding to troponin I. TnC, 
troponin C; TnI, troponin I; TnT, troponin T. Adapted from Collinson et al.52 
 
For diagnosis of myocardial damage, it has been recommended to use a cut-off value at which the 
coefficient of variation (CV) is less than or equal to 10%.10, 11 For the third generation assay this is 0.03 
µg/L. Recently, a study comparing the second and third generation assays showed excellent agreement 
(r=0.99 Spearman, p<0.0001, n=135) across the analytical range. This correlation was linear in the 
range from 0.01-0.2 µg/L and curvilinear above 0.2 µg/L.64 The third generation assay classified 35% 
more patients as having AMI, identified a 10% larger low-risk group, and was better able to identify 
patients with signs of very minor myocardial necrosis (cTnT >0.01-0.02 μg/L).65 The antibodies do not 
show cross reactivity with skeletal isoforms (<0.001%) and may therefore be used to detect cardiac 
damage in the context of exercise-induced skeletal muscle damage.13 
The fourth generation troponin T assay has recently been tested for analytical and clinical performance. 
This method differs from the previous generation in the composition of reagent 1, which has an 
inhibitor of heparin cationic activity added to make heparin plasma samples suitable for cTnT 
determination. Although preliminary data suggested a reduction of the lower detection limit with 
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adequate precision,66 the manufacturer recently determined the 10% CV concentration to be 0.028 
μg/L.67 These results were evaluated in a laboratory setting by measuring cTnT in a frozen human 
serum pool prepared by selecting fresh leftover samples from patients with cTnT concentrations around 
the selected MI cut-off. This group showed an average total CV (SD) of 9.8% (0.7) at an overall cTnT 
mean (SD) concentration of 0.041 μg/L (0.004).68 The fourth generation is now the laboratory standard 
for analysis of cTnT and a high sensitive assay with a lower detection limit is now being tested. 
Throughout the studies described in this thesis, the third generation cTnT short turnaround time (STAT) 
immunoassay was used on the Elecsys 2010 immunoassay system. In the first step, serum is combined 
with a reagent mixture containing biotinylated monoclonal anti-cTnT antibody and a ruthenium-labelled 
monoclonal anti-cTnT antibody. In the second step, streptavidin-coated paramagnetic micro particles 
are added and incubated. The now formed immune complexes are magnetically captured on an 
electrode in a measuring cell and application of a 0.2 mV voltage results in an electrochemiluminescent 
signal. This is calibrated against an internal standard curve, constructed with two calibrators. The 
serum detection limit of the third generation cTnT immunoassay, equal to the 99th percentile reference 
limit, is <0.010 μg/L.60 Between-day variation is 7.9% and 6.7% at concentrations of 0.134 μg/L and 
2.85 μg/L, respectively (n=89). It has been recommended to use a cut-off value at a concentration 
where the CV is less than or equal to 10% (0.03 µg/L).59 In the general population, however, cTnT 
elevations are rare in subjects without chronic heart failure, left ventricular hypertrophy, chronic kidney 
disease, or diabetes. It has been suggested to use the upper limit of normal should be <0.010 μg/L, 
because even minimally increased cTnT may represent subclinical cardiac injury and have important 
clinical implications.69 
Degradation of cardiac troponins 
The troponins together form a complex of three proteins. Upon cell death, these, and all other proteins 
constituting the cell, are released into the circulation. After AMI it has been shown in serum of patients 
with AMI that the predominant forms in blood are free cTnT and the cTnI-TnC binary complex.70, 71 Free 
cTnI, the cTnI-cTnT binary complex, and the cTnT- cTnI-TnC ternary complex were seldom present, and 
when present, only in small quantities compared with the binary complex.70, 72, 73 To complicate matters 
even more, cTnI was shown to be present in many different degraded and modified (phosphorylated or 
oxidized) forms.73-77 This has many analytical implications78 Because there are many manufacturers 
marketing different cTnI immunoassays, using different antibody combinations and different calibrators, 
results are not comparable between assays. Standardization of cTnI assays is essential for 
comparability of studies measuring cTnI and optimal patient care.79 
The difficulties seen with cTnI standardization are not relevant for cTnT, because there is only one 
manufacturer with a cTnT assay due to international patents (Roche). However, Wu et al. showed the 
presence of immunoreactive cTnT fragments in the circulation of AMI patients.73 Somewhat later, in a 
study by Labugger et al. on troponin I and T degradation in patients with AMI, Western blot data clearly 
showed the intact protein at ~42 kDa, one major (~26 kDa) fragment and two additional minor 
fragments (~32 kDa).75 In addition to their presence in serum, cTnT fragments have also been detected 
in healthy human heart tissue homogenates using the antibodies of the third generation cTnT 
immunoassay.80, 81 These data all support the hypothesis that, just as cTnI, cTnT is present in the 
circulation in degraded form. This might not have the standardization issues, but might aid in 
understanding the unexplained cTnT elevations sometimes encountered in clinical situations. 
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A mechanism that has been suggested for the degradation of cardiac troponins is proteolytic 
degradation. It has been shown that the calcium activated cysteine proteases such as μ-calpain (calpain 
1) and caspase-3 are capable of degrading cTnT (and cTnI) in vitro.82 Studies in the rat and mouse 
have shown that μ-calpain activation results in a 27 kDa fragment after ex-vivo ischemia and 
reperfusion of the isolated heart.83 Furthermore, addition of inhibitors of μ-calpain showed a decrease in 
this degradation reaction.83 Communal et al. showed that caspase-3 cleaves cTnT when it is in complex 
with cTnI and TnC, but not as free cTnT.84 This cleavage resulted in a 25 kDa cTnT fragment on 
Western blot when using an anti-cTnT antibody recognizing the C-terminal part of the molecule. 
In the field of expertise of clinical chemistry it is important to realize what exactly an assay measures. 
First, to fully understand the pathophysiology of a disease and, more importantly, because this allows 
for a better interpretation of the test result and advise to clinicians. As there are many diseases with 
unexplained cTnT elevations, it is necessary to clarify what is being measured. Our hypothesis is that 
degradation of cTnT results in the appearance of immunoreactive fragments. Renal impairment might 
result in the accumulation of these fragments. 
Natriuretic peptides (BNP and NT-proBNP) 
Brain natriuretic peptide was first discovered in pigs.85 Further research in humans lead to the 
unravelling of the release and effects of brain natriuretic peptides.86, 87 In humans, this natriuretic 
peptide is released mainly from the ventricular endothelium and is referred to as B-type natriuretic 
peptide (BNP).88 Figure 1-5 shows the release of BNP as the 108 amino acid prohormone proBNP, which 
is then split into the amino-terminal proBNP (NT-proBNP, 76 amino acids) and the biologically active 
BNP (32 amino acids). 
 
Figure 1-5. Release of BNP and NT-proBNP. A.a.r., amino acid residue. 
 
Upon increased stretch of the ventricular wall (e.g. increased filling pressures due to hypertension), 
BNP and NT-proBNP are released into the circulation mainly as the prohormone proBNP.89 After 
cleavage, both are present in equimolar amounts. In addition to the diuretic and natriuretic effects that 
prevent water retention and excess salt concentration, the biologically active BNP is also a peripheral 
vascular and coronary vascular vasodilator, which reduces afterload and preload of the heart. These 
properties lead to a reduction in blood pressure and thus a decrease in ventricular stress.90 BNP has 
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been shown to be a strong prognostic indicator for both asymptomatic patients and for patients with 
heart failure at all stages of disease.43, 44 
In the studies presented in this thesis, BNP was collected in EDTA plasma tubes to which the protease 
inhibitor aprotinin was added to improve stability.91 The concentration was measured with the Shionoria 
BNP assay. This is a one-step immunoradiometric assay that uses two different monoclonal antibodies 
that recognize the C-terminal structure and the disulfide bond-mediated ring structure of BNP 32.92, 93 
Between-day variation is 14,1% and 4.3% at concentrations of 1.2 pmol/L and 584 pmol/L, 
respectively (n=30). 
NT-proBNP is more stable than BNP and can be collected in serum, EDTA plasma or lithium-heparin 
plasma with good stability.94 NT-proBNP does not have a direct biological function in vivo. However, 
because BNP and NT-proBNP originate from a single precursor molecule (proBNP),95 NT-proBNP does 
have diagnostic and prognostic value in chronic and acute heart failure.89, 96, 97 In addition, elevated 
levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of other prognostic 
markers, and identify at-risk individuals even in the absence of systolic or diastolic dysfunction by 
echocardiography.98 After adjusting for confounding variables, both BNP and NT-proBNP levels were 
shown to be strongly associated with death and heart failure events in multiple studies across 
heterogeneous patient populations.99-103 Furthermore, preoperative NT-proBNP levels are a strong 
predictor of long-term mortality and major adverse cardiac events after major non-cardiac vascular 
surgery.104 
In the studies presented in this thesis, the NT-proBNP immunoassay was used on the Elecsys 2010 
immunoassay system with a sandwich principle, equal to that of the CK-MBmass assay. The serum 
detection limit of the NT-proBNP immunoassay is 0.6 pmol/L. Between-day variation is 2.4% and 2.2% 
at concentrations of 51.2 pmol/L and 800 pmol/L, respectively (n=60). The reference values for the 
identification and exclusion of acute coronary heart failure were shown to be age dependent: 53 pmol/L 
(<50 years) and 106 pmol/L pg/mL (>= 50 years).105 These cut-off values can also be used effectively 
for diagnosis of chronic heart failure.106 
OUTLINE AND AIM OF THIS THESIS 
The work presented in this thesis focuses on biochemical markers of acute coronary syndromes, in 
particular cardiac troponin T. Although this biomarker is an established and valuable laboratory 
parameter, it remains unclear in what form(s) this protein is present in the circulation. The question 
whether cTnT is present in the intact form or circulates (partly) in degraded form is relevant for assay 
accuracy. Depending on the antibody combinations used, immunoassays cannot always distinguish 
between the intact protein and its degradation products. 
Chapter 1 outlines a general introduction regarding the epidemiology and terminology of acute coronary 
syndromes (including acute myocardial infarction), the different cardiac biomarkers used for diagnosis 
and prognosis, and the laboratory assays used to measure them. This chapter also outlines the aims of 
the thesis. 
Because analysis of low abundant proteins like cTnT in an in vivo setting can be rather difficult, 
concentrating these proteins can be highly valuable. In Chapter 2 the development and optimization of 
a new and highly sensitive immunoprecipitation technique used for extracting and purifying human 
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cTnT from human serum samples is described. We analyzed serum from patients on hemodialysis to 
investigate the sometimes unexplained cTnT elevations seen in these patients. 
With this technique we then investigated the molecular forms of cTnT present in serum of patients who 
suffered an AMI (Chapter 3). We describe the changes in the composition of the molecular forms of 
cTnT. 
Using a different analytical approach, we sought to investigate the forms of circulating cTnT in an in 
vitro experimental setup. Using high performance liquid chromatography (HPLC) in combination with a 
size-exclusion chromatography column we investigated the molecular forms of cTnT (Chapter 4). 
Patient material of AMI patients was also examined. 
In Chapter 5 we analysed the available literature on cTnT elevations after endurance events such as 
marathon and triathlon. Also, the levels of cTnT seen in untrained individuals from the general 
population after a short exercise are presented and discussed. 
Chapter 6 describes in vitro experiments investigating the release of cTnT and cTnI in a model of 
cardiac ischemia using neonatal rat cardiomyocytes. 
In Chapter 7 the use of a marker for cardiac function and volume overload, NT-proBNP, is evaluated for 
its diagnostic value in diagnosing heart failure. 
Finally, Chapter 8 discusses the results and conclusions of the above mentioned studies. Furthermore, 
directions for future research will be discussed. 
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CHAPTER 2 
HIGHLY SENSITIVE IMMUNOPRECIPITATION ASSAY FOR 
EXTRACTING AND CONCENTRATING LOW ABUNDANCE PROTEINS 
FROM HUMAN SERUM – APPLICATION IN DIALYSIS PATIENTS 
ABSTRACT 
Background. Purification and identification of small, low abundance proteins like cardiac troponin T 
(cTnT) from complex samples such as serum for use in immunoblot experiments has long been a 
challenge. Commercially available immunoprecipitation methods do not always allow the use of small 
sample volumes. We have therefore developed a highly sensitive immunoprecipitation assay for 
extracting and concentrating cTnT from human serum using small sample volumes and compared it 
with a commercially available method. 
Methods. A mixture of anti-cTnT antibodies was coupled to Protein-A Sepharose and cross-linked with 
a diimidoester. We validated the method by using purified cTnT which was spiked into serum. Serum 
samples from patients with myocardial infarction were used to compare the effectiveness both 
immunoprecipitation methods. Serum samples from 63 hemodialysis patients were then used to 
determine the sensitivity of our method. SDS-PAGE and immunoblotting with monoclonal anti cTnT 
antibody 4C5 were used to visualize cTnT. 
Results. Both methods were able to concentrate cTnT. However, our method yielded higher 
concentrations and showed better results. We applied this technique to serum samples from dialysis 
patients and showed the presence of immunoreactive cTnT fragments, but not the intact protein. 
Conclusion. With our newly developed method we were able to visualize cTnT and fragments, even 
when the cTnT was below the 0.010 µg/L detection limit of the current commercially available 
immunoassay (Roche). Moreover, this method allows us to further investigate cTnT fragmentation and 
clearance in vivo. 
 
Parts of this Chapter have been published: 
Clinical Chemistry 2005;51:222-4. 
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INTRODUCTION 
Purification and identification of small, low abundance proteins from complex samples such as serum for 
use in immunoblot experiments has long been a challenge. Highly abundant proteins such as albumin 
and immunoglobulins are complicating factors, sometimes masking the presence of lower abundant 
proteins. Although many methods of effective and specific removal of albumin and immunoglobulins 
from serum and plasma samples have been described,1-3 there are some important drawbacks. In the 
circulation, albumin acts as a transporter protein that binds many (often lower abundant) proteins and 
peptides. Depletion of albumin can lead to loss of these peptides and proteins.4 The same principle goes 
for immunoglobulins that also have affinity for binding to specific molecules. In addition, left over 
patient samples (as used in this study) are usually small quantities and commercially available methods 
are not always suitable for small sample volumes. Furthermore, to avoid contamination it is best to 
provide each sample with its own set of chemicals and materials. 
 
Figure 2-1. Structure of dimethyl pimelimidate (DMP), a diimidoester, used for cross-linking of antibodies to protein-A 
Sepharose. 
 
The formation of amidines from imidoesters and amines from protein side chains was first described in 
1962 by Hunter et al., who suggested this method for cross-linking purposes.5 Levy et al. described the 
use of diimidoesters for covalent coupling of antibodies to immobilized antigens.6 Later studies reported 
similar methods for antibody immobilization with cross-linkers like dimethyl pimelimidate (DMP) and 
dimethyl suberimidate (DMS).7, 8 Both are symmetric molecules containing two identical and reactive 
imidoester groups, separated by five or six CH2 groups, respectively (Figure 2-1). 
 
Figure 2-2. Formation of amidine from an imidoester and a deprotonated amine.  
 
These methods are based on the fact that an amine is only able to react with an imidoester if it is 
deprotonated (Figure 2-2), which occurs at pH > pKa. At these pH values, the nucleophilic attack of an 
R-NH2 on one of the two outer backbone carbon atoms of DMP results in a tetrahedral intermediate that 
splits into the amidine link and methanol. Hunter et al. showed that the right choice of pH even allows a 
distinction to be made between α-amines and ε-amines 5. They showed that a pH between 7 and 8 
favors reaction with α-amines, while a pH between 9 and 10 favors reaction with ε-amines. At a pH 
between 8 and 9 both reactions occur at a significant rate. In a protein, only the N-terminal ending of a 
peptide chain contains an α-amine. The remaining amines are ε-amines from the amino acids lysine or 
arginine. The different pKa-values for lysine show that with increasing pH, first the α-amine is 
deprotonated (pKa=8.9) and subsequently the ε-amine (pKa=10.5) (Figure 2-3). The ε-amine of 
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arginine (pKa=12.5) is still protonated at pH values between 8 and 9, which leaves, besides the N-
terminal α-amine, only the ε-amine from lysine residues available for reaction. Because the variable 
regions of mouse IgG are generally almost devoid of lysine residues (Kabat Database),9 binding will 
predominantly be at constant regions, minimizing interference of the cross-linker with the antigen 
binding capacity of the antibody at pH 8.6. 
 
Figure 2-3. Deprotonation of lysine is dependent on pH. First the α-amine is deprotonated (pKa=8.9) and subsequently 
the ε-amine (pKa=10.5). 
 
Commercially available methods also use this technique. Unfortunately, these methods are usually 
marketed for large volume samples. Here we present a highly sensitive immunoprecipitation assay we 
developed for extracting and concentrating low abundant cTnT from human serum. The performance of 
our assay was compared with that of the commercially available ImmunoPure® Protein-A IgG 
orientation kit (Pierce). Both methods are based on the binding of antibodies to protein-A Sepharose 
beads and subsequent cross-linking with a diimidoester. We validated the method by using purified 
cTnT which was spiked into serum. Serum samples from patients with myocardial infarction were used 
to compare the effectiveness both immunoprecipitation methods. Serum samples from 63 hemodialysis 
patients were then used to determine the sensitivity of our method. 
METHODS 
All reactions were performed at room temperature and phosphate buffered saline (PBS) was used at pH 
7.0, unless stated otherwise. 
 
Immunoprecipitation assay 
We washed 100 mg protein-A Sepharose (Pharmacia Biotech) once with PBS and blocked with 0.1% 
bovine serum albumin (BSA) (Sigma) in PBS for 60 minutes. A mixture of anti-cTnT antibodies (9G6, 
7F4 and 1C11, Research Diagnostics Inc.; 4C5, BioSpacific/Fortron) (70 µg per antibody) in PBS with 
0.1% BSA was mixed with the Sepharose beads and rotated for one hour. After binding of the 
antibodies, the beads were washed twice with excessive PBS. Antibodies were cross-linked to protein-A 
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Sepharose by adding 200 mmol/L triethanolamine in PBS to which 20 mmol/L DMP (Sigma) was added 
directly before use (final pH 8.6). After rotation for 30 minutes the beads were washed with 200 
mmol/L triethanolamine in PBS. In contrast with the method by Schneider et al.8 and modifications 
hereon,10 cross-linking and washing were repeated twice to improve cross-linking efficiency. Remaining 
reactive amino groups were quenched by adding 50 mmol/L ethanolamine in PBS for 60 minutes. Non 
cross-linked antibodies were removed by incubating for 20 minutes with 1.0 mol/L glycine-HCl (pH 3.0) 
twice at 56ºC. Cross-linked beads were stored at 4ºC in PBS with 0.02% Tween-20 (PBST) and 0.02% 
sodium azide until use. Loading of the Sepharose beads to the column of the ImmunoPure® Protein-A 
IgG orientation kit was done with the same mixture of anti-cTnT monoclonal antibodies (285 µg per 
antibody) and was cross-linked according to the manufacturer’s instructions. 
The immunoprecipitation of cTnT (37 kDa) required 8 mg (dry weight) antibody-coupled Sepharose 
beads per sample for our method. To each tube 250 µL serum, 100 µL urea (6 mol/L) and 150 µL wash 
buffer (PBS with 0.01% Tween-20 (PBST) and 0.7 g/100 mL non-fat dry milk (Protifar Plus) (Nutricia, 
Cuijk, The Netherlands) were added. Beads were rotated for 90 minutes and then washed twice with 
PBST. Elution was performed by heating (56ºC) for 20 minutes in 100 µL 1.0 mol/L glycine (pH 3.0). 
The sample was centrifuged and supernatant was kept for analysis. 
For the ImmunoPure® Protein-A IgG orientation kit, a total amount of 750 µL serum was diluted in 300 
µL urea (6 mol/L) and 750 µL wash buffer was added to the column. After incubation for 90 minutes, 
the column was washed twice with PBS. Elution was performed with 4 times 1 mL 1.0 mol/L glycine-HCl 
(pH 3.0). Based on the presence of cTnT, fraction 3 was collected for analysis. 
Samples were prepared for electrophoresis by adding 20 µL sample buffer (40 mmol/L Tris, 3.3% (w/v) 
SDS, 50% (v/v) glycerol, bromophenolblue) to 80 µL eluate. Twenty µL of this mixture was applied to a 
4-15% linear gradient Tris-HCl polyacrylamide precast gel (Biorad). Precision Plus Protein Standard 
(BioRad) was used for molecular weight determination. After stacking for 15 minutes at 100 V and 
running for 40 minutes at 150 V, blotting was done onto a nitrocellulose membrane (BioRad) at 4°C at 
100 V for 60 minutes. Each membrane was blocked for 60 minutes in PBS with 3.3 g/100 mL non-fat 
dry milk. The primary anti-cTnT antibody (4C5) was added 1/1000 in wash buffer at 4°C overnight. 
Control experiments with a different anti-cTnT antibody (9G6; mapped epitope: 1 – 60) were also 
performed (Figure 2-1). The membrane was washed three times in wash buffer and the secondary 
antibody (peroxidase labeled goat-anti-mouse, Dako) was added 1/5000 in wash buffer for 60 minutes 
at 4°C. The membrane was washed 4 times with wash buffer and finally once in PBST. Membranes were 
developed using Enhanced Chemiluminescence Buffer and captured on Kodak X-Omat Blue film (both 
from Perkin-Elmer Life Sciences). 
To evaluate both methods, we used serum samples that were obtained from a patient with AMI. In 
addition to a total protein content of 50 g/L, these samples contained a relatively small amount of 
cTnT: sample 1 was taken 16 hours after onset of symptoms (cTnT=33.44 µg/L) and sample 2 was 
taken 238 hours after onset of symptoms (cTnT=5.53 µg/L). We tested the sensitivity of our method in 
a clinical setting and collected serum samples from 63 end stage renal disease (ESRD) patients, 
currently on hemodialysis. Patients were recruited from the in-hospital dialysis department of the 
University Hospital Maastricht. Signed informed consent was obtained from all patients. Venous blood 
samples were collected prior to dialysis, allowed to clot and centrifuged. Samples were stored at -20ºC 
and analyses were performed within one week. 
cTnT concentrations were measured with a third-generation cTnT test (Roche, Elecsys 2010). The 
serum detection limit of this immunoassay, equal to the 99th percentile reference limit, is <0.010 
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μg/L11 Between-day variation is 7.9% and 6.7% at concentrations of 0.134 μg/L and 2.85 μg/L, 
respectively (n=89). 
RESULTS 
Method validation 
Various parameters were checked to determine the optimal conditions. Protein-A Sepharose was 
preferred over protein-G Sepharose, because the latter showed more background signal in the 
immunoblots. Temperatures (37, 56, 65 and 100˚C) for the elution of cTnT from the beads showed 
optimal results at 56˚C. Finally, the difference between goat-anti-mouse and rabbit-anti-mouse 
secondary horseradish peroxidase labelled antibodies was investigated. The former resulted in slightly 
higher band intensities (data not shown). 
 
Figure 2-4. Immunoblot analysis of cTnT purified from serum from a patient with AMI visualized with monoclonal anti-
cTnT antibody 4C5. Lane 1: cTnT negative serum spiked with purified human cTnT. Lanes 2 and 3: serum sample 1 
(cTnT: 33.44 µg/L). Lanes 4 and 5: serum sample 2 (cTnT 5.53 µg/L). Lane 6: negative control. Samples in lanes 1, 2, 4 
and 6 are precipitated with our assay and samples in lanes 3 and 5 are precipitated with the Pierce Protein-A IgG 
Orientation Kit. Molecular weight standards are indicated on the left. 
 
A positive control (purified cTnT standard in cTnT negative serum) was precipitated to check whether 
the protein of interest was modified or degraded along the process. This resulted in only one band at 
~37 kDa and a small band at ~25 kDa (Figure 2-4 lane 1). A negative control serum was used to check 
for binding of proteins resulting in non-specific bands: no bands were visible. A comparison between 
the results of the two methods shows that the commercially available method from Pierce (lanes 3 and 
5) results in a lower signal. Although (much) longer exposure times revealed comparable protein bands, 
indicating similar purifying properties, background noise was becoming too high (data not shown). 
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Dialysis patients 
Table 2-1 gives the characteristics of the 63 participants in this study. Patients were relatively old (70 
years), most had hypertension (71%), 51% had a history of cardiovascular disease and the median 
time on dialysis was 26 months. Immunoblots were prepared and repeated if necessary. Due to 
differences in exposure times, band intensities are not comparable between immunoblots (Figure 2-5). 
All patients showed the presence of immunoreactive cTnT fragments, ranging in size from 8 to 25 kDa. 
The latter fragment was present in all patients, whereas the intact 37 kDa protein could not be detected 
in any of the samples. Immunoreactive fragments were also detected in samples with cTnT 
concentrations below the 0.010 µg/L detection limit of the cTnT immunoassay. 
DISCUSSION 
Cardiac troponins are low abundance proteins (µg/L) in the circulation. The reference concentration in a 
normal population has been found to be 0.0002±0.001 μg/L, as measured with the second generation 
cTnT assay,12 although this is questionable looking at the specifications of the assay used.13 This poses 
a difficulty for analysing these proteins. 
Using diimidoesters as a cross-linker between antibodies and protein-A Sepharose, we have developed 
a powerful and highly sensitive immunoprecipitation method for extracting and concentrating low 
abundance cTnT from human serum. Furthermore, there was minimal interference of high 
concentrations of total protein, albumin and human immunoglobulins when using this technique in 
combination with immunoblotting. 
 
Table 2-1. Patient characteristics (n=63). Data are represented as median values (IQR). 
Characteristic Value Reference value 
Age (years) 70 (58-76)  
Gender (male / female) 53 / 47  
Smoking (%) 35  
Diabetic (%) 18  
Hypertension (%) 71  
History of cardiac disease (%) 51  
Time on dialysis (months) 26 (15-51)  
Troponin T (µg/L)† 0.051 (0.027-0.097) <0.03 
CK-MBmass (µg/L) 1.85 (1.22-2.51) <4.9 (men) <2.9 (women) 
Myoglobin (µg/L) 157 (118-204) 28 - 72 (men) 25 - 58 (women) 
† Values below the 0.010 µg/L detection limit of the cTnT immunoassay were arbitrarily replaced by 0.005 µg/L. 
 
One important property of our method is that the amount of Sepharose beads can easily be adjusted to 
the amount of sample available. This has two advantages. First, to prevent contamination, it is best to 
allow each sample a fresh batch of Sepharose beads. This can easily be done with our method, whereas 
with the use of (large volume) columns this will be more expensive (in terms of the number of columns 
and antibodies needed). Also, this requires large sample volumes that are not always readily available. 
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Secondly, because of the low volume elution (50 μL), proteins remain present at relatively high 
concentrations. Therefore, this method is extremely suitable for extracting and concentrating low 
abundance (µg/L) proteins from small sample quantities without the risk of cross-contamination. 
Elevated cTnT levels have been reported in many different diseases, including primary systemic 
amyloidosis,14 acute stroke,15 idiopathic dilated cardiomyopathy,16 congestive heart failure,17 
myocarditis,18 pulmonary embolism,19 cardiac surgery,20 major vascular surgery,21 cardiotoxicity,22 
sepsis,23 patients with chronic kidney disease,24 ESRD patients on dialysis,25 and many other.26, 27 
 
Figure 2-5. Immunoblots of 63 dialysis patients showing the ability of our assay to detect cTnT, even at concentrations 
below the 0.010 µg/L detection limit of the third generation cTnT assay (Roche). Indicated below the panels are the 
sample number and the cTnT concentration (µg/L). Immunoblotting was done with monoclonal antibody 4C5 and all 
immunoblots were aligned at 25 kDa. Intensities are not comparable due to different exposure times. 
 
The scientific discussion has focussed mainly on troponin elevations in ESRD patients, because minor 
cTnT elevation are often seen in this population. Clinicians have difficulties with interpreting these levels 
in the acute setting, because the concentrations are often around or above the 0.03 µg/L AMI cut-off 
level. We showed that the cTnT concentration correlated well with the duration on dialysis.28 When we 
hypothesized that immunoreactive fragments may well be the cause of these minor increases, this was 
subject of discussion.29 The main issue that has been investigated is the prognostic value of cardiac 
troponins (I and T) in this population. It has been shown that elevated cTnT or cTnI levels have a 
higher morbidity and mortality rate, compared with ESRD patients without troponin elevations.25, 30, 31 
In conclusion, using this highly sensitive method we were the first to detect cTnT fragments in serum 
samples from dialysis patients, even at concentrations below the 0.010 µg/L detection limit of the third 
generation cTnT assay. Possibly, these immunoreactive fragments remain in the circulation, despite 
being small enough to be cleared by the kidney. It is possible these fragments give a positive reaction 
in the commercially available cTnT immunoassay marketed by Roche. This method allows us to further 
investigate cTnT fragmentation and clearance in vivo. 
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CHAPTER 3 
INVESTIGATION OF RELEASE AND DEGRADATION OF CARDIAC 
TROPONIN T IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
ABSTRACT 
Background. Cardiac troponin T (cTnT) degradation after tissue release is still under debate. Because 
degradation of cTnT might have consequences on clearance of the molecule from the circulation, but 
also on the assay performance, the aim of this study was to investigate cTnT release and degradation in 
serum of AMI patients.  
Methods. Serum samples were collected from 20 patients with AMI diagnosis undergoing rapid 
revascularization. Intact cTnT and fragments were detected using a combination of 
immunoprecipitation, SDS-PAGE and Western blotting. 
Results. The intact cTnT protein was detected only during the first 12 hours after the cTnT 
concentration started to increase above the AMI cut-off value of 0.03 µg/L. Thereafter only fragments 
with molecular weights ranging from 10 – 30 kDa were detected, with two fragments being most 
prominent (15 and 25 kDa). 
Conclusions. Intact cTnT rapidly disappears from the circulation during the early hours after AMI, but 
immunoreactive fragments remain present longer. The current cTnT immunoassay detects both intact 
cTnT and fragments. 
 
Parts of this Chapter have been published: 
Clinical Biochemistry 2007; 40:851-5. 
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INTRODUCTION 
Cardiac troponin I (cTnI) and T (cTnT) have been recommended as the biomarkers of choice for 
diagnosis and prognosis of acute myocardial infarction (AMI) because of their high sensitivity and 
specificity.1 Both proteins are markers of cardiomyocyte necrosis, which is accompanied by increased 
proteolytic activity. Especially cTnI has been shown to be highly susceptible to degradation after 
myocardial infarction.2-5 It is likely that degradation of cardiac troponins after AMI can have 
consequences for both release into and clearance from the circulation. In addition, the 
immunoreactivity of the intact protein and its degradation products can be different. For cTnI, 
degradation has been shown to be a key factor in assay-to-assay variation, thereby complicating the 
standardization of different cTnI assays.5, 6 
Because of an international patent there is only one manufacturer providing commercially available 
cTnT assays, so that the results between different studies are easier to compare. However, degradation 
or modification of cTnT (just as cTnI) during and after AMI might influence cTnT immunoreactivity. 
Therefore, knowledge on the different circulating forms of cTnT is essential for further determination of 
assay characteristics and accuracy, but also to investigate the influence on release characteristics and 
clearance from the circulation of the molecule. In addition, this knowledge might shed light on the 
unexplained cTnT elevations seen in many diseases.7 
Degradation has been described for both cTnT2, 8 and cTnI2, 3 in serum of patients with AMI. Also, in an 
earlier study, we demonstrated degradation of cTnT in serum from patients with end stage renal 
disease.9 In addition to their presence in serum, cTnT fragments have also been detected in human 
heart tissue homogenates.10, 11 Contrasting these studies, Fahie-Wilson et al. recently stated that in 
patients with kidney failure cTnT circulates only in the intact form.12 To the best of our knowledge, 
there have been two reports describing both intact cTnT and fragments in serum of patients with AMI. 
The first study used serum samples from three patients and applied these to gel filtration 
chromatography.8 The second study detected one major (~26 kDa) and two minor degradation 
products with a direct-serum-analysis Western blot technique in serum from one patient.2 The latter 
study clearly indicated a time related difference in the forms of cTnT present in serum. 
A possible relation between release characteristics and cTnT degradation has not been investigated until 
now. Katus et al. were the first to describe the biphasic release kinetics of cTnT after AMI.13 The typical 
biphasic release kinetics can be seen when early coronary revascularization is achieved. When 
revascularization is not achieved, the initial rapid rise in cTnT is reduced and only the second peak 
around 3-4 days after onset of symptoms is found. The rationale behind it is thought to be the 
intracellular compartmentation of cTnT.14, 15 In human myocardium, approximately 6% of cTnT is found 
as an unbound cytosolic fraction that can be released rapidly after cell damage. The remaining cTnT, 
which is bound to the myofibrils, is released more slowly over a prolonged timespan. The 
electrophoretic and immunogenic properties of the bound and unbound cTnT forms were found to be 
similar.14 
In the present study we investigated for the first time circulating cTnT molecules at different times after 
AMI, using a highly sensitive immunoprecipitation assay, SDS-PAGE and Western blotting. 
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METHODS 
Patients 
Serum samples sent to our laboratory for clinical analysis were collected from 20 patients with AMI 
diagnosis undergoing rapid revascularization. Samples were stored at -20ºC and used for 
immunoprecipitation and Western blotting within 6 months. All consecutive routine samples were 
collected during hospitalization. Informed consent for analysis of cTnT and its fragments in leftover 
serum after routine analysis of cardiac markers was obtained. The investigation conforms to the 
principles outlined in the Declaration of Helsinki. Six patients arrived at the Emergency Department 
(ED) with a cTnT concentration below the AMI cut-off value of 0.03 µg/L. The time after onset of 
symptoms for these 6 patients was between 2-6 hours. We determined the time where the cTnT 
concentration was still below the AMI cut-off value as the starting point of the time concentration curve. 
All individual curves were curve-fitted (Figure 3-1A). In the 14 patients without a sample with a cTnT 
concentration below the AMI cut-off value the curve was extrapolated. The median time for each 
consecutive sample in the serum cTnT concentration curve was calculated relative to the starting point 
of the curve for each individual patient. Based on these release kinetics, the curve was divided into 6 
different points (0-5). 
A serum pool was prepared from blood of five healthy volunteers with the cTnT concentration below the 
assay detection limit. This serum pool was used as a negative control and precipitated as described to 
check for non-specific binding of the antibody. Two commercially available troponin T standards were 
spiked into the negative serum pool and used as positive controls in Western blotting: A highly purified 
(>98%) human cTnT standard (Advanced ImmunoChemical Inc., Long Beach, USA) and the recently 
characterised and certified Standard Reference Material (SRM) 2921 for standardization of cardiac 
troponin I assays,16 composed of the human cardiac troponin complex (HyTest Ltd., Turku, Finland). 
Analytical methods 
cTnT was measured on an Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Germany) using the 
third-generation cTnT immunoassay (capture antibody M11.7 recognizing amino acid residues 136-147 
and detection antibody M7 recognizing residues 125-131).10, 11 The AMI cut-off concentration is 0.03 
µg/L and the detection limit is 0.01 μg/L.17 Between-day variation (expressed as CV) is 7.9% and 6.7% 
at concentrations of 0.134 μg/L and 2.85 μg/L, respectively (n=89). 
Western Blotting 
Serum samples were thawed and cTnT was extracted and concentrated according to the method we 
described earlier.9 In brief, samples were prepared for SDS-PAGE by adding 20 μL of sample buffer (40 
mmol/L Tris, 33 g/L SDS, 500 mL/L glycerol, and bromophenol blue) to 80 μL of concentrated cTnT 
sample. We applied 20 μL of this mixture to a 4-15% linear gradient Tris-HCl polyacrylamide precast 
gel (Biorad, Veenendaal, The Netherlands). The Precision Plus Protein Standard (Biorad) was used as 
the molecular weight marker. After stacking for 15 minutes at 100 V and running for 45 minutes at 150 
V, the gel was blotted onto a 0.45 μm nitrocellulose membrane (Biorad) at 4ºC at 100 V for 60 
minutes. The membrane was blocked for 60 minutes in PBS containing 33 g/L non-fat dry milk 
(Nutricia, Cuijk, The Netherlands). The primary monoclonal anti-cTnT antibody (4C5, BiosPacific, 
Emeryville, USA) was added at a 1:1000 dilution in wash buffer (PBS containing 0.2 mL/L Tween-20 
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and 6.7 g/L non-fat dry milk) and incubated overnight at 4ºC. The membrane was washed three times 
5 minutes in wash buffer and the secondary antibody (peroxidase-labelled goat-anti-mouse, DAKO, 
Glostrup, Denmark) was then added at a 1:5000 dilution in wash buffer and incubated for 60 minutes 
at 4ºC. The membrane was washed four times 5 minutes in wash buffer and finally once in PBS for 10 
minutes. The membrane was developed with Enhanced Chemiluminescence Buffer (Perkin-Elmer, 
Boston, USA) and captured on Kodak X-Omat Blue film. 
Statistical analysis 
Values are represented as medians (interquartile range, IQR), unless stated otherwise. Statistical 
analysis was done with SPSS 11 for Windows. The overall differences between the different points of 
the serum cTnT time concentration curve were tested with the non-parametric Kruskal-Wallis test. 
Because there was a significant difference (p<0.01), the non-parametric Wilcoxon signed rank test was 
used for analysis of differences in the number of fragments and their mean molecular weight at the 
different points in the curve. Bonferroni correction was used to adjust for multiple testing. A p-value 
<0.05 was considered to indicate a statistically significant difference. 
RESULTS 
Release kinetics for cTnT showed a biphasic change in the serum time concentration curve of each 
individual patient. This was, however, not perfectly clear from the median concentration represented in 
the combined curve (Figure 3-1A). The median (IQR) cTnT peak concentration of these patients was 9.0 
μg/L (10 μg/L). The median times after the starting point of the curve (point 0) were 8 (6), 12 (7), 37 
(46), 94 (55) and 169 (116) hours for point 1, 2, 3, 4 and 5 on the curve, respectively. Figure 3-1B 
shows a Western blot example of one representative patient, clearly showing the time dependent 
changes. Intact cTnT migrated to approximately 37 kDa on SDS-PAGE. Evidence for the presence of the 
troponin TIC complex (~79 kDa) was not found in any of the patients, likely due to the effects of SDS. 
Two researchers independently counted the number of cTnT fragments per sample and determined 
their mean molecular weight based on the molecular weight markers. These data are represented as 
individual measurements in Figure 3-2. 
Intact cTnT was detected in 15 out of the 20 patients, but only within the first 12 hours after the cTnT 
concentration started to increase above the AMI cut-off value of 0.03 µg/L. This was the part of the 
curve in which the cTnT concentration increased to the maximum value. In 3 of these 15 patients, the 
intact protein was the only molecule detected in serum at point 0, without the presence of fragments. 
In the other patients fragments were also present at and from point 0 (Figure 3-2B). In blood samples 
after the cTnT peak concentration at 12 hours, no intact cTnT could be detected and only fragments 
were identified. 
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Figure 3-1. Serum cTnT concentration changes after acute myocardial infarction. 
A) Combined cTnT time concentration curves of 20 AMI patients with early revascularization. The serum concentration 
changes are represented as median (line) and interquartile range (dotted lines). Based on these release kinetics, the 
curve was divided into 6 different points, indicated by the numbers 0-5. B) Representative Western blot analysis of 
serum from one patient with AMI. Lane 1, positive control with the intact cTnT migrating to approximately 37 kDa; lanes 
2 and 10, molecular weight markers; lanes 3-9, serum samples at 0.5, 6, 11, 25, 106, 137 and 209 hours after onset of 
symptoms. Lane 11, serum with cTnT undetectable when measured by the third generation cTnT assay. Cardiac troponin 
T concentrations are given above the corresponding lanes. 
 
Figure 3-2. The number of cTnT fragments and their mean molecular weight after acute myocardial infarction. 
A) The number of cTnT fragments per sample (also including the intact molecule) increased in the first 12 hours (point 0-
2) and then decreased slowly with immunoreactive cTnT fragments still present in the circulation at point 5. B) In 15 
patients, intact cTnT was detected, but only within the first 12 hours (point 0-2). In 3 of these 15 patients, intact cTnT 
(37 kDa) was the only molecule that could be detected at point 0. In 12 other patients the intact protein was 
accompanied by smaller fragments from point 0. The intact protein rapidly disappeared from the circulation, but smaller 
fragments remained present for up to 169 hours. N=6, 11, 20, 20, 17 and 14 at a median of 0, 8, 12, 37, 94 and 169 
hours after point 0, respectively. The non-parametric Wilcoxon signed rank test with Bonferroni correction was used for 
calculating differences. 
 
Figure 3-2A gives the number of fragments detected in each individual. Figure 3-2B shows the mean 
molecular weight of all detected fragments (including the intact molecule), which was highest directly 
after cTnT values started to increase above the AMI cut-off (point 0, 34.0 kDa). From the peak cTnT 
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concentration at 12 hours, the mean molecular weight of all fragments decreased from 21.0 kDa to 
19.2 kDa at a median of 37 hours (p=0.006), 17.0 kDa at a median of 94 hours (p=0.006) and 16.9 
kDa at a median of 169 hours (p=0.012) after the initial rise of cTnT at point 0, respectively. 
At the peak cTnT concentration the median number of circulating cTnT fragments had increased to 5, 
with two fragments of 25 and 15 kDa being most prominent (Figure 3-1B). The prolonged elevation of 
cTnT concentrations, as determined by the current commercial cTnT assay was still clearly evident at a 
median of 169 hours after the initial rise of cTnT above the AMI cut-off concentration. Importantly, at 
this time the intact protein had already disappeared from the circulation. Hence, the positive result in 
the cTnT assay can therefore only be explained from immunoreactivity of cTnT fragments, indicating 
that the current commercial assay detects both intact cTnT and its fragments. 
DISCUSSION 
In the present study we investigated degradation of circulating cTnT in samples from patients with AMI 
at different times after cTnT values started to increase above the AMI cut-off. With a highly sensitive 
immunoprecipitation assay and Western blotting, we were able to detect intact cTnT and up to 10 
different fragments in serum from patients diagnosed with AMI. Fragments, ranging in size from 10 – 
30 kDa, were detected in all studied patients. The intact cTnT protein, however, was detected only 
within the first 12 hours in which the cTnT concentration reached its maximum, but never in later 
samples. These data indicate that the current commercial cTnT assay measures both intact cTnT and its 
fragments. These data also suggest a very short half-life for the intact cTnT molecule. This is in 
accordance with the report by Katus et al. who described the half-life of cTnT in serum to be 120 
minutes, and claimed that a persistent serum elevation of cTnT beyond the 5th day after onset of 
symptoms could not be attributed to slow elimination from the circulation, but indicated ongoing cTnT 
release during infarct evolution, most likely being the fraction bound to the myofibrils.14 
The presence of intact cTnT and its fragments in serum of AMI patients has been reported earlier by 
other groups.2, 8 In the study by Wu et al., serum samples from three patients at or around the peak 
troponin values were used and subjected to gel filtration chromatography analysis.8 The different peaks 
were assigned to the troponin TIC complex, free cTnT and immunoreactive fragments. We were not 
able to detect the troponin TIC complex due to the effects of SDS. Around the peak cTnT values we also 
found the intact protein accompanied by several fragments. In a study by Labugger et al. on troponin I 
and T degradation, Western blot data with serum from one patient and probed for cTnT showed the 
intact protein, one major (~26 kDa) fragment detected at 6:40 hours and two additional minor 
fragments (>26 kDa) at 17:25 hours after the first blood sample was drawn.2 
Contrasting these studies, Fahie-Wilson et al. recently investigated the nature of circulating cTnT forms, 
using gel-filtration chromatography or size exclusion chromatography (SEC), combined with off-line 
measurement of cTnT. The main conclusion of their paper was that cTnT circulates predominantly in the 
free, intact form in serum of patients with kidney failure and in patients with acute coronary 
syndrome.12 Importantly, however, no secondary proof was provided by either SDS-PAGE or mass 
spectrometry. Further analysis of their data indicated that these conclusions could, however, be 
incorrect with part of the immunoreactive molecules present in patients with acute coronary syndrome 
and in patients on hemodialysis or peritoneal dialysis being immunoreactive cTnT fragments.18-20 
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In addition to the presence of cTnT fragments in serum of patients with AMI,2, 8 and patients on 
hemodialysis,9, 21 fragments have also been detected in healthy human heart tissue homogenate, using 
the monoclonal antibodies from the third generation Roche cTnT immunoassay. This leads to another 
relevant question. Does degradation of cTnT (and cTnI) occur inside the cardiomyocyte, or is cTnT 
degraded after release of the intact protein into the circulation? Our study was not designed to provide 
this information. In our patients, both the intact protein and its fragments were present in serum early 
after the initial rise of cTnT, suggesting that fragments may have already been generated inside the 
cardiomyocyte, before loss of membrane integrity and reperfusion as suggested by Labugger et al.,2 
Van der Laarse also hypothesized that release of troponin and/or troponin fragments is not specific for 
necrotic myocardium, but may also occur from viable myocardium.22 Indeed, there is evidence 
suggesting degradation of cTnT within the cardiomyocyte by protease activity related to myocardial 
damage.23 
Calcium dependent proteases, such as calpain I and II have been shown to be activated due to the 
intracellular Ca2+ overload that develops during ischemia and early reperfusion.24, 25 The specific 
degradation of cTnT by calpain I has been demonstrated in vitro and in situ in rats26 and in guinea 
pig.27 More recently, Bartha et al. showed that activation of calpain I resulted in one cTnT degradation 
product of 33 kDa using human heart tissue.28 Intact cTnT migrated to 44 kDa on SDS-PAGE. In our 
experimental settings, cTnT migrated to 37 kDa on SDS-PAGE and the main fragment to 25 kDa. The 
intact cTnT to fragment ratio deduced from their data gives 44/33=1.33 and calculations on our data 
give a ratio of 37/27=1.37, suggesting similarity in detected molecules. 
The apoptotic protease caspase-3 has also been shown to be capable of degrading cTnT in vitro. 
Communal et al. showed that caspase-3 cleaves cTnT when it is in complex with cTnI and TnC, but not 
as free cTnT.29 Cleavage resulted in a 25 kDa cTnT fragment on Western blot when using an anti-cTnT 
antibody recognizing the C-terminal part of the molecule. It is possible that after AMI proteases 
involved in apoptosis and or necrosis degrade structural proteins (including cTnT) before loss of 
membrane integrity, resulting in the release of fragments, in addition to the intact protein. 
Based on the data presented here and the available literature, we believe that the rapid increase of 
cTnT concentrations in patients with early reperfusion mainly represents release of the intact protein 
from the cytosolic fraction as already hypothesized by Katus et al.14 We hypothesize this fraction is 
rapidly cleared from the circulation after AMI, which has also been suggested for cTnT clearance after 
strenuous exercise.30 Furthermore, it is likely that the prolonged elevations of cTnT seen after AMI can 
be ascribed to the formation of immunoreactive cTnT fragments and likely some release of the intact 
protein. It is possible that these immunoreactive fragments have a different (longer) half life, thereby 
giving rise to the typical biphasic release curve seen after AMI. 
 
In conclusion, we have shown that the current commercial cTnT assay detects both intact cTnT and 
several of its fragments. Furthermore, we showed that intact cTnT rapidly disappears from the 
circulation during the early hours after AMI.  
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CHAPTER 4 
INTERPRETATION OF CARDIAC TROPONIN T BEHAVIOUR IN SIZE-
EXCLUSION CHROMATOGRAPHY 
ABSTRACT 
Background. Knowledge about the presence of intact cardiac troponin T (cTnT) and/or its 
immunoreactive fragments is of great value for the interpretation of cTnT clearance from the 
circulation. Until now there has been a lot of controversy on cTnT fragmentation. To provide an answer 
to the present controversy, we investigated fragmentation of cTnT with size-exclusion chromatography 
(SEC), and confirmed our data with mass spectrometry. 
Methods. A highly purified human cTnT standard, characterized with mass spectrometry as one single 
peak of 34377 Da, and with SDS-PAGE as one single immunoreactive band (37 kDa), was incubated in 
serum for 0, 24 and 48 hours at 37°C and analyzed using SEC. A troponin TIC complex standard, used 
in an earlier study, was also investigated. 
Results. We demonstrated that, because of its rod like shape, the molecular weight of cTnT cannot be 
estimated from SEC using the molecular weight of globular proteins as a reference. The Stokes radius 
of intact cTnT was calculated to be 33.7 Å. Incubation of both cardiac troponin standards in troponin 
free serum resulted in a time dependent decrease of intact cTnT and in a simultaneous increase of 
smaller immunoreactive fragments (13.4 Å and 22.4 Å). 
Conclusion. cTnT has a Stokes radius of 33.7 Å. Compared with globular calibrator proteins, intact 
cTnT elutes earlier than can be expected based solely on its molecular weight. For non-globular or 
uncharacterized proteins, stokes radii should be used for correct interpretation of SEC data. By doing 
so, we were able to clearly demonstrate cTnT fragments. 
 
Parts of this Chapter have been published: 
Clinical Chemistry 2006;52:2306-7. 
Clinical Chemistry and Laboratory Medicine 2006;44:1422-7. 
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INTRODUCTION 
Several studies have discussed the presence of circulating cardiac troponin T (cTnT) fragments in 
patients with acute myocardial infarction (AMI). The latest contribution to the discussion has been by 
Fahie-Wilson et al.,1 who investigated the nature of cTnT reactive molecules in serum samples of 
dialysis patients and in patients with acute coronary syndrome using gel-filtration chromatography or 
size-exclusion chromatography (SEC). In this study it was claimed that the circulating cTnT in patients 
with kidney failure and elevated serum cTnT concentrations was due to the presence of the free, intact 
molecular form of cTnT 1. They also showed that the cTnT elution profiles of patients that experienced 
an acute coronary event were identical to the patients with kidney failure which contrasts to the study 
by Wu et al., who reported the presence of immunoreactive cTnT fragments in serum after AMI using 
the same technique.2 
Troponin T fragments have already been described in the early days of troponin investigation.3, 4 
Although these experiments focused mainly on bovine cardiac troponins, it is reasonable to assume that 
similar results will be obtained for human troponins. Comparison of the amino acid sequences of human 
and bovine cardiac troponins in the online SWISS-PROT database indicated 85%, 89% and 99% 
homology between bovine and human cardiac troponin T, I and C, respectively.5 Similar homology has 
been described for human and bovine cTnT by others.6 More recently, Labugger et al. also 
demonstrated cTnT fragments in serum after AMI with the use of a western blot– direct serum analysis 
protocol. Importantly, they showed a time related change in the composition of the fragments.7 Later, 
Diris et al.8 and Michielsen et al.9 showed the presence of cTnT fragments in serum of hemodialysis 
patients. 
When investigating proteins with SEC, it is important to realize that cTnT is far from globular. 
Numerous studies have already addressed the important influence of the hydrodynamic volume / 
molecular shape of proteins on the chromatographic behaviour in a SEC column.10-15 Ideally, the 
distribution of a molecule into the pores of a SEC column is only a matter of steric interaction or 
hydrodynamic volume. 
The hydrodynamic volume of a protein can be expressed as the Stokes radius (Rs) and is a generally 
accepted method for data interpretation in SEC.12 A non-globular protein is known to have a (much) 
larger Rs compared to a globular protein with an equal molecular weight. Several mathematical models 
have been proposed for the description of the behaviour of non-globular proteins in SEC.11, 13 Although 
none of these models are completely correct, there is general agreement that separation of non-
globular proteins in a SEC column is better described using the Stokes radii of the proteins than using 
their molecular weights.10 In contrast, when using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) for molecular weight determination, it is possible to directly compare 
molecular weights with known molecular weight standards. With this technique there is a linear relation 
between the length of the molecule and the amount of SDS bound to it, and chromatographic behaviour 
is primarily determined by the negative electrical charge from SDS. 
Evidently, when using SEC, the molecular weight of a cTnT molecule, which has a rod like shape,16, 17 as 
well as the molecular weight of the troponin TIC complex, cannot be determined directly from a 
molecular weight calibration curve using globular calibration proteins. The intact cTnT molecule is most 
likely to elute from the SEC column much earlier than could be expected based on its relatively large 
Stokes radius. To test this theory for human cTnT, we performed SEC experiments using a Superdex 75 
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SEC column, SDS-PAGE and immunoblotting, and mass spectrometry (MS). Further characterization of 
serum cTnT and/or its fragments was performed using these three techniques. 
METHODS 
To be able to compare our data with previous findings, we not only used a highly purified (>98% pure) 
human cTnT standard (Advanced Immunochemical Inc, Long Beach, USA), but also purchased the less 
well characterized troponin TIC complex standard (SCIPAC, Sittingbourne, England) used by Fahie-
Wilson et al.1 MS was used to confirm the molecular weight of all troponin standards. For this purpose, 
a PBS-IIc time-of-flight mass spectrometer (Ciphergen Biosystems Inc, Freemont, USA) was calibrated 
in the molecular range of 12-147 kDa. Troponin standards were applied directly to a Matrix Assisted 
Laser Desorption/Ionization (MALDI) surface (2 µL). A saturated sinapinic acid (Ciphergen) solution in 
50% acetonitrile, 0.5% trifluoracetic acid was used as the energy absorbing matrix (two 1 µL 
additions). 
In addition, SDS-PAGE and immunoblotting were performed with monoclonal anti-cTnT antibody 9G6 
(HyTest, Turku, Finland), recognizing amino acid residues 1-60. Troponin standards were directly 
diluted to the appropriate concentrations in Laemmli sample buffer (Biorad, Veenendaal, The 
Netherlands) before application to the electrophoresis gel. We applied 20 µL of this mixture to a 4-15% 
linear gradient Tris-HCl polyacrylamide precast gel (Biorad). The Precision Plus Protein Standard 
(Biorad) was used as the molecular mass marker. After stacking for 15 minutes at 100 V and running 
for 45 minutes at 150 V, the gel was blotted onto a 0.45 µm nitrocellulose membrane (Biorad) at 4ºC at 
100 V for 60 minutes. The membrane was blocked for 60 minutes in PBS containing 33 g/L nonfat dry 
milk (Nutricia, Cuijk, The Netherlands). The primary monoclonal anti-cTnT antibody (9G6) was added at 
a 1:1000 dilution in wash buffer (PBS containing 0.2 mL/L Tween-20 and 6.7 g/L nonfat dry milk) and 
incubated overnight at 4ºC. The membrane was washed three times 5 minutes in wash buffer and the 
secondary antibody (peroxidase-labeled goat-anti-mouse, DAKO, Glostrup, Denmark) was then added 
at a 1:5000 dilution in wash buffer and incubated for 60 minutes at 4ºC. The membrane was washed 
four times 5 minutes in wash buffer and finally once in PBS for 10 minutes. The membrane was 
developed with Enhanced Chemiluminiscence Buffer (Perkin-Elmer, Boston, USA) and captured on 
Kodak X-Omat Blue film. 
SEC experiments were performed on a Hewlet-Packard 1100 system (Agilent Technologies) equipped 
with a Superdex 75 10/300 GL SEC column (Pharmacia Biotech) and a diode array detector (210-900 
nm). Ammonium bicarbonate (0.1 mol/L) was used as running buffer at a flow of 0.25 mL/min to 
facilitate easy transfer to the mass spectrometer. All samples were loaded onto the column with a 200 
μl injection loop. Equation 4-1 was used to translate elution volumes into dimensionless theoretical 
fractional volumes: 
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where Kav is the theoretical fractional volume of the column to which the sample of interest has access, 
Ve is the elution volume, V0 is the void volume of the column (7.55 mL) and Vt is the total volume of the 
column (25 mL). 
The low molecular weight calibration standard (Pharmacia Biotech, cat. no. 17-0442-01) was composed 
of a mixture of four globular proteins: bovine serum albumin (67 kDa, 35.5 Å), ovalbumin (43 kDa, 
30.5 Å), chymotrypsinogen A (25 kDa, 20.9 Å) and ribonuclease A (14 kDa, 16.4 Å) 18. Dextran Blue 
(2000 kDa) was used to determine V0 of the column. Between 20 and 100 minutes, fractions of 0.5 mL 
were collected every two minutes. cTnT concentrations were measured on an Elecsys 2010 analyzer 
(Roche Diagnostics) with the third generation cTnT assay, with a serum detection limit of <0.010 µg/L. 
Between-day variation is 7.9% and 6.7% at concentrations of 0.134 µg/L and 2.85 µg/L, respectively 
(n=89). Cardiac troponin I (cTnI) was measured with the Access AccuTnI assay (Beckman Coulter, Inc, 
Fullerton, USA). Between-day variation is 3.0% and 4.1% at concentrations of 0.56 µg/L and 7.31 
µg/L, respectively (n=120). 
Pooled serum, obtained from healthy volunteers and negative for both cTnT and cTnI, was spiked with 
the purified cTnT standard and incubated for 0, 24 and 48 hours at 37ºC. The negative control was also 
incubated for 48 hours. All samples were separated on the SEC column to investigate possible 
degradation due to protease activity. Identical experiments were done using the troponin TIC complex 
standard, although incubation times were slightly different (0, 24 and 96 hours). 
RESULTS 
Elution profile of globular calibration standards 
Figure 4-1 panel A shows the elution profile of the four globular calibration proteins. The volume at 
peak maximum was used for calculation of Kav and construction of the calibration curve. When Kav was 
plotted against ln(Rs), the calibration curve for these experimental settings was obtained (Figure 4-1 
panel B). With the calibration curve, Kav=-0.278 ln(Rs) + 1.077 (equation 4-2), it is possible to calculate 
Stokes radii of uncharacterized proteins. For this Superdex 75 column, the Rs separation window (Kav 
between 0 and 1) lies between 1.3 Å and 48 Å. Any protein with a Rs larger than 48 Å will elute at V0 
(7.55 mL) and any protein smaller than 1.3 Å at Vt (25 mL). 
Properties of the cardiac troponin standards 
Figure 4-2 panels A and B show the mass spectra of the two cardiac troponin standards. The purified 
cTnT standard showed one peak at m/z value 34378, corresponding to the molecular weight of the 
single protonated intact protein ([M+H]+). Also visible was a smaller peak at approximately half the 
m/z value (17307), representing the double protonated cTnT molecule [M+2H]2+. In addition, there was 
also a peak at m/z value 68545, corresponding to [2M+H]+. In contrast, the major component of the 
troponin TIC complex standard was albumin (m/z value 66318, [M+H]+). Again, the smaller peak at 
m/z value 33238 represented the double protonated albumin molecule [M+2H]2+. This mass spectrum 
neither showed peaks at the expected m/z values of the individual troponin T, I or C subunits, nor the 
TIC complex. It is questionable whether cTnT can be detected at all, due to the relatively high 
concentration of albumin (5.6 g/L), which is known to cause ion suppression. 
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Figure 4-1. Calibration of the Superdex 75 column. (A) Elution profile of four globular proteins. The theoretical fractional 
volume (Kav) was calculated from equation 4-1. The void volume (V0) was determined by elution of Dextran Blue. The 
total column volume (Vt) was obtained from the specifications provided by the manufacturer (Vt=25 mL). (B) Calibration 
equation (equation 4-2) used for calculation of the Rs of uncharacterized proteins. 
 
 
Figure 4-2. Characterization of two cardiac troponin standards. (A) Mass spectrum of a purified cTnT standard showing 
intact protonated cTnT at m/z value 34378 ([M+H]+). (B) Mass spectrum of a troponin TIC complex standard showing 
albumin at m/z value 66318 ([M+H]+) as the major component. (C) Elution profile of both cardiac troponin standards 
spiked into serum and applied directly to SEC. cTnT was measured with the third generation Roche cTnT immunoassay. 
 
Figure 4-2 panel C shows both standards spiked into serum and applied directly to SEC. The SCIPAC 
TIC complex standard showed two cTnT reactive peaks, whereas the purified standard showed one peak 
superimposed on a column artefact (baseline elevation). 
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SDS-PAGE confirmed the presence of the intact protein at 37 kDa in the purified cTnT standard. 
Although partly obscured by the large amount of albumin, the troponin TIC complex standard also 
showed the intact protein. However, a cTnT fragment at ~27 kDa was most prominent (Figure 4-3). 
Albumin removal (ProteoExtract Albumin Removal Kit, Calbiochem) did not yield better results (data not 
shown). 
 
Table 4-1. Summary of chromatographic data. 
 Molecular weight
(kDa) 
Ve 
(ml) 
Kav Stokes radius 
(Å) 
A. Calibration proteins 
Ribonuclease A 13.7 12.79 0.301 16.4 
Chymotrypsinogen A 25.0 11.49 0.226 20.9 
Ovalbumin 43.0 9.82 0.130 30.5 
Bovine serum albumin 67.0 8.96 0.081 35.5 
B. cTnT reactive peaks 
Peak 1 34 * 9.25 0.097 33.7 † 
Peak 2  11.25 0.212 22.4 † 
Peak 3  13.75 0.355 13.4 † 
* Molecular weight as confirmed a priori by mass spectrometry; † Stokes radius calculated from equation 4-2. 
 
 
Figure 4-3. Immunoblot of two cardiac troponin standards applied directly to SDS-PAGE. Lane 1, purified cTnT standard. 
Lane 2, SCIPAC troponin TIC complex standard. Lane 3, Molecular weight marker (kDa). Detection was done with 
monoclonal anti-cTnT antibody 9G6 (epitope 1-60, HyTest). The intact protein is partly masked by the large amount of 
albumin present in the troponin TIC complex standard. 
 
In-vitro incubation of troponin standards in serum 
Figure 4-4 panels A and 4B show the elution profiles of the purified cTnT standard and the troponin TIC 
complex standard, respectively. Both cardiac troponin standards were spiked into the pooled troponin 
negative serum and incubated for 0, 24 and 48 or 96 hours at 37ºC. The x-axis (elution volume) and y-
axis (cTnT concentration) have been kept similar for both samples for easier visual comparison. Two 
major peaks are visible. In time, the amount of troponin T eluting in Peak 1 (Kav= 0.097, Rs= 33.7 Å) 
decreased, whereas the amount eluting in Peak 2 (Kav= 0.212, Rs= 22.4 Å) increased. Note that Peak 2, 
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because of its later appearance, represents a molecule that is smaller than the first peak with a 
molecular weight of 34377 Da, as confirmed by MS. After 96 hours of incubation, the troponin TIC 
complex standard showed a third peak (Peak 3, Kav= 0.355, Rs= 13.4 Å), indicating an even smaller 
immunoreactive cTnT molecule. A summary of these chromatographic data is given in Table 4-1. 
DISCUSSION 
When using SEC for molecular weight determination of uncharacterized proteins, it is important to 
realize the molecular mechanism behind the technique. Although the ideal situation can be described 
quite precisely, laboratory practice has proven to be different. When trying to label a peak with a 
certain molecular weight, thorough knowledge about the sample, as well as calibrators and standards 
are of utmost importance. 
 
Figure 4-4. Incubation of cardiac troponin standards in serum. (A) Elution profile of the purified cTnT standard 
incubated in serum for 0, 24 and 48 hours. (B) Elution profile of the troponin TIC complex standard incubated in serum 
for 0, 24 and 96 hours. Both cardiac troponin standards showed a decrease in cTnT concentration for Peak 1 and an 
increase for Peak 2. The troponin TIC complex standard incubated for 96 hours even showed a third immunoreactive 
cTnT peak. cTnT was measured with the third generation Roche cTnT immunoassay. 
 
Behavior of proteins in SEC is determined mainly by their hydrodynamic volume (expressed as Stokes 
radius, Rs). Nonglobular proteins are known to have a larger Rs than globular proteins with a 
comparable molecular weight, and cTnT is far from globular.17 Therefore, as is generally agreed, the 
separation of the nonglobular cTnT protein in an SEC column is better described with the Rs than the 
molecular weight.10 The latest contribution to the discussion on cTnT fragmentation was by Fahie-
Wilson et al.1 The interpretation of these data appeared to be incorrect, as outlined below. 
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From the data by Fahie-Wilson et al.1 we calculated the Rs of the immunoreactive peaks. To do so, we 
deduced the Kav of the calibrator proteins from Figure 1 (ribonuclease A, 0.393; chymotrypsinogen A, 
0.310; ovalbumin, 0.165) and constructed a new calibration curve (Kav vs ln Rs). To construct this curve 
we used the Stokes radii of these proteins: 16.4 Å, 20.9 Å, and 30.5 Å, respectively.18 This calibration 
curve is represented by equation 4-3: 
 
Kav=-0.369 Ln(Rs) + 1.427; R2=0.999 (4-3) 
 
The void volume (V0) of the column was estimated from the reported column volume (Vt) of 75 mL and 
from the elution volume (Ve) and Kav of the globular proteins albumin (Ve=31.4 mL; Kav=0.118) and 
prolactin (Ve=40.2 mL; Kav=0.280). Entering these numbers into the equation for Kav: Kav=(Ve–V0)/(Vt–
V0), yielded a V0 of 25.1 mL (albumin) and 26.4 mL (prolactin). The mean of 25.8 mL was used as an 
estimate of the true V0. 
We then calculated the Kav for the 2 cTnT reactive peaks from Figure 2D (peak 1, Ve=30.5 so Kav=0.09; 
and for peak 2, Ve=37.0 so Kav=0.22). When these Kav were entered into equation 4-3, Stokes radii of 
37 Å and 26 Å were obtained. In addition, we used equation 1 to calculate the highest Rs (Kav=0) that 
could be separated with the column (Rs,max=48 Å). We believe these Rs do not correspond to the 
troponin complex and free cTnT. The Rs of the troponin complex has been determined to be 57 Å.19 
Hence, we may conclude that the first peak cannot correspond to the troponin complex, because this 
would have eluted at V0. 
It is plausible, however, that the first peak corresponds to intact free cTnT. Based on the Rs of bovine 
TnC (18.4 kDa) and cTnI (23.9 kDa) (24 Å and 30 Å, respectively,20 it is likely that the larger cTnT 
(34.5 kDa) has an Rs of 37 Å. The online SWISS-PROT database indicated 85%, 89%, and 99% 
homology between bovine and human cardiac troponin T, I, and C, respectively. The second peak would 
then correspond to an immunoreactive fragment. Interestingly, a small immunoreactive fraction just 
before 30 mL is visible in Figure 2C and corresponds to the first peak from Figure 2D 1. This peak could 
indicate a small amount of the intact protein present in ACS patients. Importantly, because no 
secondary proof was provided (e.g. SDS-PAGE or amino acid sequencing), the exact identity of the 
peaks remains unclear. 
Regarding our data, the purified cTnT standard showed the presence of only one protein with a 
molecular weight of 34377 Da as confirmed by MS and similar to the expected mass of intact cTnT 
(Figure 4-2A). In contrast, the troponin TIC complex standard neither showed a peak at the expected 
molecular weight of the troponin TIC complex (77 kDa), nor at the expected position of individual 
subunits T, C and I. This might be attributable to (a) the effects of the MALDI technique that can cause 
separation of the TIC complex into the 3 individual troponin subunits, combined with (b) the relatively 
high (5.6 g/L) albumin concentration resulting in suppression of the troponin signals. Therefore, the 
absence of a peak at m/z value ~77000 in Figure 4-2B may not lead to the conclusion that no troponin 
TIC complex is present. Also, under denaturing conditions, as with SDS-PAGE, protein complexes are 
likely to be separated into the individual subunits. This might explain why the native TIC complex was 
not detected in our experiments. 
For the bovine cardiac troponin TIC complex, a Stokes radius of 52-57 Å has been found.4, 19 The online 
SWISS-PROT database indicated 85%, 89% and 99% homology between bovine and human cTnT,6 I 
and C, respectively.5 In our opinion, this justifies application of these bovine data to human troponins. 
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The properties of the Superdex 75 column limit the highest Stokes radius that can be determined to 48 
Å. Therefore, the intact troponin TIC complex should, if present, elute at V0 (Kav=0). 
Separation of the cardiac troponin standards should result in either one peak for the purified cTnT 
standard (intact cTnT), and one, maybe two peaks for the troponin TIC complex standard (troponin TIC 
complex, and intact cTnT). Keeping in mind the non-globular shape of cTnT, the actual elution volumes 
for both intact cTnT and the troponin TIC complex will be shifted towards larger elution volumes. 
Importantly, the peak of the troponin TIC complex will elute earlier than the peak of the intact cTnT. 
Surprisingly, when both cardiac troponin standards were loaded onto the column, both showed a similar 
elution profile (Figure 4-2C), revealing two major peaks. In combination with the data derived from the 
MS experiments with the purified cTnT standard, this leads to the following conclusions: (a) In the 
absence of troponin I and C, Peak 1 of the purified cTnT standard (of which the contents has been 
confirmed by MS) can only be intact cTnT, not the TIC complex; (b) the Rs of Peak 1 (33.7 Å) is too 
small for the earlier reported Rs of 52-57 Å for the troponin TIC complex,4, 19 thus supporting the first 
conclusion; (c) following conclusion (a), Peak 2 must be an immunoreactive fragment of cTnT, most 
likely the ~25 kDa fragment described by our group,9 and others;7, 21 (d) based on identical elution 
volumes, the two peaks of the troponin TIC complex standard can only represent intact cTnT and a 
smaller immunoreactive fragment; (e) with the current chromatographic conditions, the TIC complex is 
unstable and disintegrates into its subunits; (f) the Rs of intact human cTnT is 33.7 Å. 
In vitro incubation of both cardiac troponin standards in serum showed a time dependent decrease of 
Peak 1 and at the same time, an increase of Peak 2. For the troponin TIC complex standard a third, 
even smaller fragment appeared at t=96 h. The small cTnT reactive peak, only present after 24 or 48h 
of incubation of the highly purified cTnT standard (Figure 4-4A) suggests the presence of a molecule 
with a higher Rs than intact cTnT. Possible cTnT aggregation16 does not interfere with the measured Rs 
of this fraction (which is only slightly bigger than the Rs of the monomer) when it is assumed that the 
two rod like molecules adhere along the long-axis. Evidently, it cannot be the troponin TIC complex due 
to the absence of cTnI and the fact that it would elute at V0. Based on the previous conclusions this 
degradation of cTnT confirms earlier experiments where in vitro incubation of spiked serum samples 
showed the appearance of smaller degradation products in time on SDS-PAGE (Figure 1 in the online 
data supplement of Michielsen et al.9). 
In conclusion, from the fact that comparable Stokes radii were found in our study compared with the 
results described by Fahie-Wilson et al.1 and from the fact that the molecular mass of the purified cTnT 
standard was independently confirmed by MS and SDS-PAGE, we may conclude that the peaks 
indicated by Fahie-Wilson et al.1 cannot be the troponin TIC complex and free cTnT, but are intact cTnT 
and an immunoreactive cTnT degradation product (most probably of approximately 25 kDa). Hence, the 
correct conclusion from the study by Fahie-Wilson et al.1 should have been that in patients on 
hemodialysis or peritoneal dialysis, no intact free cTnT is present, but a smaller (25 kDa) 
immunoreactive cTnT fragment is. In patients with acute coronary syndrome a small amount of the 
intact free protein is present, depending on the time after onset of symptoms. Moreover, this conclusion 
is strengthened by the fact that incubation of a purified cTnT standard in troponin free serum resulted 
in a time dependent increase of immunoreactive fragments, which has been demonstrated in this study 
by SEC chromatography and in an earlier study by our group using SDS-PAGE.9 With our current 
findings we clearly demonstrated that a thorough approach to interpretation of SEC data is of utmost 
importance. Furthermore, fragmentation of cTnT in serum was clearly demonstrated using different 
techniques. 
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Limitations of the study 
Because of the unavailability of the unlabelled anti cTnT antibodies of the Roche third generation cTnT 
assay a different anti-cTnT antibody had to be used. Therefore, it should be noted that (quantitative) 
data from the immunoblots cannot directly be compared to the peak height of the SEC data. 
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CHAPTER 5 
CARDIAC TROPONIN T RELEASE AFTER PROLONGED STRENUOUS 
EXERCISE AND RECREATIONAL EXERCISE 
ABSTRACT 
Over the past two decades there has been a large interest in cardiac troponin T (cTnT) elevations, 
which are often seen following endurance sport events. There have been many reports on this topic, 
although sometimes with different approaches. We reviewed the available literature on cTnT elevations 
after prolonged strenuous exercise and found profound differences in the percentage of subjects 
reported to have elevated cTnT concentrations. This could partly be attributed to differences in 
immunoassay characteristics, such as cross-reactivity with skeletal troponin T, and the use of different 
cut-off values used in the different studies. The elevations were transient, with levels decreasing to pre-
event concentrations within 24 to 48 hours. This might be explained by the relatively short half life of 
cTnT, or water imbalance during and after the event. The release mechanism of cTnT, as well as the 
long term positive or negative effects, remains unclear. Future research should therefore be aimed at 
clarifying the release mechanism of cTnT. Furthermore, the benefits and the possible long term 
negative aspects of prolonged exercise should be evaluated. 
 
Parts of this Chapter will be published: 
Sports Medicine 2007; Accepted for publication. 
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INTRODUCTION 
Healthy food and an active lifestyle are factors that are generally associated with a lower risk of cardiac 
disease. Many people worldwide participate in a variety of physical activities, some more intense than 
others. Prolonged exercise, such as training for and participating in a marathon or triathlon, is 
becoming more popular. On average, participants in these strenuous activities are well-trained 
individuals pursuing a healthy lifestyle. There is, however controversy on the beneficial effects of 
prolonged exercise. In the past several years, studies have been published that showed the release of 
cardiac biomarkers after prolonged exercise in healthy participants. An example of these biomarkers is 
troponin. Troponins are markers that are used in a clinical setting to detect cardiac tissue damage and 
to diagnose acute myocardial infarction.1 The problem between prolonged exercise and troponin 
elevations is that it is unknown whether this release indicates reversible or irreversible damage to the 
heart. The current review aims to summarize all published literature regarding the release of cardiac 
troponin T (cTnT) after prolonged strenuous exercise to gain insight in the frequency of cTnT elevations 
and the influence of different immunoassays used for detection. 
THE TROPONIN COMPLEX 
The troponin complex is comprised of three subunits and regulates Ca2+ dependent muscle contraction 
in all striated muscle cells. Troponin T structurally binds the troponin complex via troponin C to 
tropomyosin. Binding of Ca2+ to troponin C results in increased affinity for troponin I. Troponin I then 
releases its inhibitory function on actomyosin ATPase, which leads to ATP hydrolysis and muscle 
contraction (see Farah et al.2 for an extensive review). Troponins are present in cardiac and skeletal 
muscle. The isoforms of troponin I and T, however, are encoded by different genes, yielding 
immunologically different proteins in cardiac and skeletal muscle.3, 4 The cardiac muscle isoforms of 
troponin I and T (cTnI and cTnT, respectively) are highly specific and highly sensitive biomarkers for 
detecting minor cardiac damage.5 Hence, cTnI and cTnT are the preferred biomarkers for diagnosis and 
prognosis of acute coronary syndromes.1, 6 It was demonstrated that the diagnosis of myocardial injury 
can be accurately excluded within 6 hours of admission using cTnT at the time of initial presentation, 3 
and 6 hours after presentation resulting in sensitivities of 79.7%, 95.7%, and 98.4%, respectively.7 
PROLONGED EXERCISE 
The name "marathon" comes from a legend. According to the Greek historian Herodotus in his book 
“History”, the Athenian generals sent Pheidippides, a professional runner, from Athens to Sparta to ask 
the Spartans to help fight the Persian army, who had arrived by ship at Marathon. Pheidippides 
completed the 145 mile (234 km) journey, delivered the generals' request, and then returned to Athens 
with the Spartan's reply - which was that due to religious festivities they could not leave Sparta until 
the first full moon. Upon receiving this news the generals decided to attack the Persians anyway, the 
result being Athenian victory against seemingly overwhelming odds in the Battle of Marathon (490 BC). 
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The alternative version of the legend says that Pheidippides was sent from the town of Marathon to 
Athens (about 26 miles, 42 km) to announce that the Persians had been miraculously defeated. It is 
said that he ran the entire distance without stopping. Moments after proclaiming the Greek victory over 
Persia with the words "We were victorious!”, he died on the spot.8, 9 
Fortunately, death is an infrequent occurrence in modern day marathons,10-12 but there is debate about 
the clinical cardiac aspects of prolonged strenuous exercise. Although regular exercise is associated 
with certain cardiac benefits,13 biochemical markers of cardiac tissue damage such as the cardiac 
troponin isoforms cTnI,14-16 and cTnT15-20 have been shown to be elevated immediately after prolonged 
strenuous exercise. These effects were all transient and returned to normal values within 24 to 48 
hours. This review aims to give an overview of the cTnT elevations reported after prolonged strenuous 
exercise and to discuss the possible role of the different assay generations used for determining cTnT 
concentrations. 
TROPONIN T IMMUNOASSAYS 
Ever since it became apparent that antibodies against the cardiac isoform of troponin T were able to 
discriminate between skeletal and cardiac isoforms, immunoassays have been developed and 
improved.21 In 1989 the first generation cTnT immunoassay was released. This was a one step ELISA 
method, which employed polyclonal goat-anti-human anti-troponin T antibodies, immobilised on 
polyvinylchloride test tubes and peroxidase labelled monoclonal anti-troponin T antibody 1B10 for 
detection.22 The latter had 12% cross reactivity to skeletal muscle troponin T.23, 24 Overall, the assay 
displayed 1% cross reactivity to skeletal TnT,22 likely attributable to unspecific binding of skeletal 
muscle troponin T to the test tube and detection by the cross-reactive monoclonal antibody 1B10 used 
as label.25, 26 The detection limit of this assay was 0.04 µg/L and the turnaround time was 90 minutes. 
Some years later, the assay (Enzymun®) was improved by replacing the capture antibodies with biotin 
labelled monoclonal capture antibody M7, without significant cross reactivity to skeletal TnT, and 
antibody 1B10 for detection, combined with streptavidin-coated tubes as the solid phase to reduce 
unspecific binding.23 
The second generation, a new and more-specific version of the troponin T ELISA, was developed and 
used a new antibody combination.26 The second generation cTnT immunoassay used two cardiac tissue 
specific monoclonal anti-cTnT antibodies, biotin labelled monoclonal capture antibody M11.7 
(recognising amino acid residues 136-147) and horseradish peroxidase labelled monoclonal detection 
antibody M7 (recognising amino acid residues 125-131). The latter was first used as capture antibody. 
The detection limit of this assay was lower (0.0123 µg/L), the imprecision was lower and the 
turnaround time was reduced to 45 minutes.26, 27 Calibration of the assay was performed with purified 
bovine cTnT spiked in human serum. For diagnosis of patients with myocardial damage a cut-off of 0.1 
µg/L was proposed.26 
The third generation assay used recombinant human cTnT as calibration material and had a more linear 
calibration curve. Thus, linearity problems observed with the second generation assay were eliminated. 
The assay had high precision, especially at the low end of the measuring range.28 The detection limit in 
serum and heparin plasma is <0.010 µg/L, which is equal to the 99th percentile reference limit in 
healthy volunteers.29, 30 However, heparin was shown to generate markedly decreased concentrations 
CHAPTER 5 
62 
compared with serum.31, 32 Speth et al. concluded that the apparent decrease in cTnT values in heparin 
plasma was a result of direct molecular interaction between the negatively charged glycosaminoglycan 
and clusters of basic residues within the cTnT molecule.33 For diagnosis of myocardial damage, it has 
been recommended to use a cut-off value at which the coefficient of variation (CV) is less than or equal 
to 10%. For the third generation assay this was 0.03 µg/L. It was shown to be a valuable marker that 
allows for rapid and accurate differential diagnosis of patients with suspected acute coronary syndrome, 
and of patients with other causes of chest pain.34 Recently, a study comparing the second and third 
generation assays showed excellent agreement (r=0.99 Spearman, p<0.0001, n=135) across the 
analytical range. This correlation was linear in the range from 0.01-0.2 µg/L and curvilinear above 0.2 
µg/L.35 The third generation assay classified 35% more patients as having AMI, identified a 10% larger 
low-risk group, and was superior in identifying patients with signs of very minor myocardial necrosis 
(cTnT >0.01-0.02 μg/L).36 The antibodies do not show cross reactivity with skeletal isoforms 
(<0.001%) and may therefore be used to detect cardiac damage in the context of exercise-induced 
skeletal muscle damage.37, 38 
The fourth generation troponin T assay has recently been tested for analytical and clinical performance. 
This method differs from the previous generation in the composition of reagent 1, which has an 
inhibitor of heparin cationic activity added to make heparin plasma samples suitable for cTnT 
determination. Although preliminary data suggested a reduction of the lower detection limit with 
adequate precision,39 the manufacturer recently determined the 10% CV concentration to be 0.028 
μg/L.40 These results were evaluated in a laboratory setting by measuring cTnT in a frozen human 
serum pool prepared by selecting fresh leftover samples from patients with cTnT concentrations around 
the selected cut-off for diagnosis of myocardial infarction. This group showed an average total CV (SD) 
of 9.8% (0.7) at an overall cTnT mean (SD) concentration of 0.041 μg/L (0.004).41 The fourth 
generation is now the laboratory standard for analysis of cTnT. 
CARDIAC TROPONIN T AND PROLONGED EXERCISE 
It is generally known that participants in endurance sport events can have abnormal laboratory 
parameters, including electrolytes and biomarkers for cardiac function.42, 43 An extensive table of 
modified reference ranges (or expected ranges) for basic biochemical, cardiac, and haematologic 
laboratory parameters for marathon runners was published recently.43 In general, these abnormal 
values returned to normal within 24 to 48 hours after the strenuous event, suggesting these effects are 
transient. 
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Especially cTnT has been investigated thoroughly in the past two decades (Table 5-1). The data 
presented in Table 5-2 is a summary of the data presented in Table 5-1. The first generation assay 
recognised skeletal and cardiac troponin T in 44% of the subjects. Subsequent studies using the second 
generation showed a lower percentage positive subjects (13%), possibly because of loss of the skeletal 
component. Most studies used the third generation cardiac specific assay, which showed cTnT 
elevations in 59% of the subjects, likely due to the 10-fold lower detection limit. We could not detect 
differences between the kind of exercise (running or cycling, marathon or triathlon) and the severity of 
cTnT increases in these studies. It has been shown that cTnT elevations correlated inversely with 
training distance, suggesting that adaptation of the heart to strenuous exercise can decrease cardiac 
injury.44 In contrast to the findings by Fortescue et al. who found that younger age appeared to be 
associated with cTnT increases,45 other groups reported no relation with age.17, 46-48 
At first the difficulty was to differentiate the skeletal isoform from the cardiac isoform of troponin T. 
When this was achieved with the arrival of the second generation cTnT immunoassay, the scientific 
discussion focussed more on the short and long term clinical aspects of cTnT elevations. The most 
important and difficult question to be answered was whether the release of cTnT in healthy athletes 
after strenuous exercise represents transient and reversible myocardial damage, or subclinical and 
irreversible myocardial damage. A recent meta-analysis revealed an overall immediate post exercise 
reduction in the ejection fraction (EF), systolic blood pressure/end systolic volume (SBP/ESV) ratio, and 
early-to-late diastolic filling (E/A) ratio, suggesting a transient decrease in both systolic function and 
diastolic filling.49 More recently, it was shown in 20 subjects that all the systolic abnormalities had 
normalised after a marathon race, but that diastolic abnormalities of the left and right ventricle 
persisted up to 1 month after participation.50 It has been argued that, despite the claims of exercise 
induced damage, the cardiovascular benefits attributable to regular vigorous exercise are the primary 
prevention strategy for coronary disease.51 
 
Table 5-2. cTnT elevations as measured with different Roche cTnT immunoassay generations. 
Assay generation Number of studies Number of subjects Number of subjects 
with cTnT elevation* 
1th generation 12 279 122 (44%) 
2nd generation 7 205 27 (13%) 
3rd generation 26 1290 759 (59%) 
Cardiac Reader 2 66 5 (8%) 
* Different cut-off values have been used in different studies. 
TROPONIN RELEASE 
Although the exact mechanism of release remains to be clarified, it has been hypothesised that these 
elevations most likely reflect (reversible) myocardial stunning and/or true (irreversible) ischemic cell 
injury and even cell death.18, 52 Transient elevations could represent loss of cTnT from the cytosolic pool 
due to membrane damage induced by oxidative stress,53 hypoxia,54 or transient ischemia.52 Regarding 
this, exercise has been shown to induce overload of free oxygen radicals leading to increased 
membrane leakage.55, 56 The majority of the total intracellular cTnT content is bound to the myofibrils in 
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complex with cTnI and troponin C. Marked differences in release kinetics of cTnT have been described 
in patients with reperfusion after acute myocardial infarction, compared to patients with a permanent 
occlusion. Rapid reperfusion (> 3.5 hours), resulted in a typical biphasic cTnT time-concentration 
curve.57, 58 The early rapid rise (first peak) in serum concentrations was ascribed to release of cTnT 
from the unbound cytosolic fraction and the persistent elevation (second peak) of cTnT for more than 
180 hours after onset of symptoms to ongoing cTnT release from myofibrils.57 From the biphasic release 
curve it is apparent that the half-life of the cytosolic fraction is considerably shorter than the half-life of 
the second, bound fraction. It was hypothesised that the return of elevations observed directly after 
exercise to pre-race levels can be ascribed to the relatively short (120 minutes) half life of cTnT.19 It is 
also possible that cTnT concentrations after one day are below the detection limit of the current routine 
Roche immunoassay due to water imbalance. It has been shown that during and shortly after a 
marathon race plasma volume is decreased, which resulted in a loss of body weight and an increase of 
serum albumin.59 It is likely that cTnT is also concentrated due to a lower plasma volume. In addition, a 
significant increase in plasma volume was noted at 24 and 48 hours after running a treadmill 
marathon.60 The increase in plasma volume results in dilution and this might explain why elevations of 
cTnT decrease below the detection limit 24-48 hours after a race. 
The other cardiac specific isoform of troponin (cTnI) has also been shown to be elevated after 
prolonged strenuous exercise.15, 55, 61, 62 Proteolysis and degradation of cTnI have been extensively 
investigated.63, 64 A recent study showed that degradation of cTnI in human myocardium might impair 
diastolic function, whereas systolic function was largely preserved.65 
The cellular release mechanism of troponin is likely different from that after myocardial infarction. A 
possible role of catecholamine-induced myocardial injury after exercise has been proposed.66 In 
addition, it was shown that the cardiovascular response to dobutamine was abnormal with attenuated 
heart rate, blood pressure and left ventricular contractility, suggesting it may be due, in part, to altered 
β-receptor function.67 
SHORT EXERCISE 
Neilan et al. recently reported an intriguing paper, confirming signs of myocardial injury of Boston 
Marathon participants, showing an inverse correlation between decreased cardiac function and elevated 
biomarkers such as cardiac troponin T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-
proBNP).68 cTnT was elevated above the 99th percentile of normal (>0.01 ng/ml) in > 60% of 
marathon participants, while 40% of the studied participants had cTnT levels above the limit for acute 
myocardial infarction (≥0.03 μg/L). Since the authors excluded participants with a previous history of 
cardiovascular disease, a relatively healthy population was studied. The accompanying editorial stated 
that it is important to study the long term sequelae of prolonged exercise among minimally trained 
runners.69 
In this light, our recently collected data contain a message that may be even more disturbing. We 
studied serum cardiac biomarkers in 127 participants in a 4 mile health run/walk before and after the 
event, which was an activity to promote a healthy life style and physical activity in the general 
population. The study was approved by the local medical ethics committee. Venous blood samples were 
collected 0,5-2,5h before the event, and 0,5-2,5h post-event for the determination of cTnT and NT-
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proBNP (Roche Diagnostics). Subjects were required to fill in a questionnaire and had their blood 
pressure measured in order to calculate the risk score according to the PROCAM study (Table 5-3).70 
Mean age was 53±11 years. NT-proBNP was elevated above the age-adjusted optimal cut-off for heart 
failure71 pre-event in one subject (178 pmol/L), with post-event levels being elevated in this subject 
(280 pmol/L) and one other subject (118 pmol/L). Troponin levels were elevated above the 99th 
percentile of normal in 3 subjects post-event, and in two subjects even above the cut-off for myocardial 
infarction (0.011; 0.036 and 0.102 μg/L), whereas pre-event cTnT levels were undetectable. These 
subjects had PROCAM risk scores of 10.4, 0.8 and 7.8%, and post-event NT-proBNP levels of 43, 22 
and 20 pmol/L, respectively. The mean PROCAM risk score for all participants was 7.0±11%, the mean 
NT-proBNP pre and post-event were 13±19 and 18±29 pmol/L, respectively. 
 
Table 5-3. Characteristics of 127 participants with a post-race blood sample. 
Characteristic All (n=127) Male (n=63) Female (n=64) 
Age 55 (13-75) 55 (13-73) 55 (14-75) 
Systolic blood pressure (mmHg) 137 (110-189) 135 (110-189) 140 (110-177) 
Cholesterol (mmol/L) 5.5 (3.3-9.4) 5.5 (3.3-9.4) 5.6 (3.3-8.8) 
HDL (mmol/L) 1.2 (0.6-2.5) 1.1 (0.6-2.3) 1.5 (0.7-2.5) a 
LDL (mmol/L) 3.7 (1.8-6.4) 3.9 (2.1-6.4) 3.6 (1.8-6.3) 
Triglycerides (mmol/L) 1.0 (0.3-3.7) 1.1 (0.4-3.7) 0.9 (0.3-2.6) 
Glucose (mmol/L) 5.7 (4.6-9.5) 5.8 (5.0-9.5) 5.6 (4.6-7.7) 
Pre-race NT-proBNP (pmol/L) 7.7 (0.6-178) 6.0 (0.6-178) 9.0 (1.9-91) a 
Post-race NT-proBNP (pmol/L) 10 (0.6-280) 7.8 (0.6-280) 12 (1.3-118) b 
Pre-race cTnT (μg/L) 0.010 (0.010-0.010) 0.010 (0.010-0.010) 0.010 (0.010-0.010) 
Post race cTnT (μg/L) 0.010 (0.010-0.102) 0.010 (0.010-0.102) 0.010 (0.010-0.011) 
PROCAM Risk score (%) 3.6 (0.1-88) 2.9 (0.1-88) 4.8 (0.2-59) b 
History of smoking (no/yes) (%) 106/20 (84/16) 46/16 (74/26) 60/4 (94/6) a 
History of MI in family (no/yes) (%) 84/42 (67-33) 40/22 (65/35) 44/20 (69/31) 
Data are represented as median (minimum - maximum). cTnT measurements below 0.010 μg/L are represented as 
0.010 μg/L. a p<0.01, b p<0.05 
CONCLUSIONS 
There has been ongoing research on the clinical aspects of cTnT elevations sometimes seen in 
participants following endurance events such as marathons, ultra-runs, or triathlons. Based on the 
available literature we conclude that many groups have reported cTnT elevations after prolonged 
strenuous exercise in the past two decades. In these reports different cTnT immunoassays (with 
different characteristics) were used. Together with the use of different cut-off values, this clearly 
influenced the percentage of athletes reported to have cTnT elevations post-event. Using the third 
generation cTnT immunoassay, elevations above the detection limit of 0.010 µg/L occurred in 59% of 
professional and recreational athletes. The mechanism of release and the clinical long term effects 
remain to be clarified. Clinicians dealing with these athletes should always measure a second cTnT 3 to 
6 hours after the initial blood sample when the person is suspected of having mild ischemia or even a 
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myocardial infarction.7, 72 We also conclude that elevation in serum cardiac biomarkers can occur in a 
subset of subjects after a short exercise, especially when untrained. These data support the notion that 
careful preparation is not only crucial to prevent the release of cardiac biomarkers from the heart for 
extensive endurance races like a marathon, but may also be essential for exercise levels that are 
performed by millions of individuals around the world everyday. 
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CHAPTER 6 
RELEASE KINETICS OF INTACT AND DEGRADED TROPONIN I AND T 
AFTER IRREVERSIBLE CARDIOMYOCYTE DAMAGE 
ABSTRACT 
Background. For the diagnosis of acute myocardial infarction (AMI) activity assays of enzymes like 
lactate dehydrogenase (LDH) and creatine kinase (CK) have been replaced by mass assays of CK-MB, 
cardiac troponin I (cTnI) and cardiac troponin T (cTnT). This study characterized whether the release 
kinetics of cardiac troponin I (cTnI) and T (cTnT) differ from each other in cardiomyocytes before and 
after the transition from reversible to irreversible cell damage, as assessed by the release of lactate 
dehydrogenase (LDH). 
Methods. Cultures of cardiomyocytes were exposed to metabolic inhibition by treatment with sodium 
azide (1 mmol/L) to induce a necrotic cell death process that is characterized by a reversible (0-12 h) 
and irreversible phase (12-30 h). At various time intervals cells and media were collected and analyzed 
for LDH activity, intact cTnI and cTnT, and their degradation products. 
Results. During the first 12 h of metabolic inhibition, cell viability was unchanged with no release of 
intact cTnI and cTnT nor their degradation products. Between 12 and 30 h of azide treatment, 
cardiomyocytes showed progressive cell death accompanied by release of intact cTnI (29 kDa), intact 
cTnT (39 kDa), four cTnI degradation products of 26, 20, 17 and 12 kDa, and three cTnT degradation 
products of 37, 27 and 14 kDa. Possibly due to degradation, there is progressive loss of cTnI and cTnT 
protein that is obviously undetected by the antibodies used.  
Conclusions. Mild metabolic inhibition of cardiomyocytes induces a parallel release of intact cTnI and 
cTnT and their degradation products, starting only after onset of irreversible cardiomyocyte damage. 
 
Submitted for publication. 
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INTRODUCTION 
Cardiac troponin I and T (cTnI and cTnT) are highly sensitive and specific markers of myocardial injury 
in patients with acute myocardial infarction (AMI).1, 2 Within a few hours after onset of AMI, troponins 
are released from necrotic cardiomyocytes into the circulation. Typically, troponin levels peak at 16-18 
h, and remain elevated for several weeks after AMI, long after levels of most other markers have 
normalized.1, 3, 4 Despite the high cardiac specificity, several studies have demonstrated that the 
appearance of troponins in serum of patients with AMI is delayed compared with the release of CK-
MBactivity and CK-MBmass,5-8 suggesting that troponins and CK-MB do not share identical release kinetics, 
and that troponins may not be ideal early markers for ruling out AMI. Previously, we investigated the 
release kinetics of intact cTnI and lactate dehydrogenase (LDH) from cultured neonatal cardiomyocytes 
exposed to severe metabolic inhibition using sodium cyanide, which induces necrosis over a time period 
of 3-3.5 hours.9 We found that the release of intact cTnI from irreversibly damaged cardiomyocytes was 
partial and delayed as compared with the release of LDH. This delay can theoretically be explained by 
(1) slow dissociation of cTnI molecules from the myofilaments as only 3-8% of cTnI is free in the 
cytoplasmic pool,10 or (2) the early formation of cTnI degradation products that remained undetected 
by the specific ELISA that is used, as detection of cTnI degradation products is antibody dependent.11, 12 
Troponins are susceptible to proteolytic degradation by intracellular proteases, such as calpain-I, 
caspases, or matrix metalloproteinase-2 (MMP-2).13-16 Degradation products of troponins are detected 
in serum of patients with AMI, and the release pattern of these degradation products changes in the 
days following onset of AMI.14, 17-19 
In addition to troponin degradation during irreversible cell damage, several studies have suggested that 
proteolysis of troponin may also occur in reversibly damaged cardiomyocytes.20-22 
In the present study we investigated the release kinetics of cardiac troponins from cultured neonatal 
cardiomyocytes undergoing metabolic inhibition by sodium azide. Azide is an inhibitor of cytochrome c 
oxidase and induces cell death that, at 1 mmol/L, develops slower compared to cyanide at 5-10 
mmol/L. Chen et al. have demonstrated that cultured neonatal rat cardiomyocytes exposed to azide 
showed a transition from reversible to irreversible cell damage after 6-12 hours.23 The purpose of the 
present study was to characterize the release kinetics of intact cTnI, intact cTnT, and degradation 
products of cTnI and cTnT, in relation to LDH, the golden standard for cell death, from azide-treated 
cardiomyocytes before and after the transition from reversible to irreversible cell damage. 
METHODS 
Primary cultures of neonatal cardiomyocytes 
Primary cultures of cardiomyocytes were prepared from the ventricles of 2-day old Wistar rats as 
described previously.24 Briefly, ventricles were minced and cells were isolated enzymatically using 
collagenase type I (CLS, Worthington, Lakewood, NJ, USA) at 37°C. The cell suspension was centrifuged 
and the cell pellet was resuspended in growth medium. Cells were seeded in Primaria®-coated plastic 
culture dishes (∅ 6.0 cm, Falcon, Becton Dickinson, Etten-Leur, The Netherlands), and after 45 min 
non-adherent cells, i.e. the cardiomyocytes, were collected and plated in Primaria®-coated plastic 
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culture dishes at a density of ≈3x106 cells per well. Cardiomyocytes were incubated in a humidified 
incubator at 37°C and 5% CO2 and culture medium was refreshed after 20 h and 48 h. After three 
days, a monolayer of spontaneously beating cardiomyocytes had formed. The investigations had the 
approval of the Animal Experiments Committee of the LUMC, according to Dutch law. 
Metabolic inhibition of cardiomyocytes 
Three days after isolation, cardiomyocyte cultures were washed in HEPES-buffered salt solution (HBSS), 
containing (in mmol/L) NaCl (125), KCl (5), MgSO4 (1), KH2PO4 (1), CaCl2 (2.5), NaHCO3 (10), sodium 
pyruvate (5), and HEPES (20), pH 7.4 at 37˚C. In each experiment, six cultures of neonatal rat 
ventricular myocytes were exposed to metabolic inhibition by incubation in 3 mL HBSS containing 
sodium azide (1 mmol/L) for 0, 6, 12, 18, 24 and 30 h at 37˚C. 
At the end of a period of metabolic inhibition, medium was separated from the cells, cells were collected 
in 1.5 ml ice-cold lysis buffer containing (in mmol/L) Tris-HCl (20), NaCl (100), EDTA (5), 1% (v/v) 
Triton X-100, and 10% (v/v) glycerol, pH 7.5, and both cell and medium samples were kept on ice 
awaiting assay of LDH activity at the same day. Aliquots of cell and medium samples were stored at -
20˚C until cTnI and cTnT assays. 
LDH activity assay 
Necrotic cell death was quantified by assay of LDH activity released from cells into medium, according 
to Wroblewski and Ladue.25 After various periods of metabolic inhibition (0 to 30 h), LDH activities in 
medium and cell samples were determined using a spectrophotometer (Ultrospec 3000, Pharmacia, 
Roosendaal, The Netherlands) at 25oC. Per culture tested, the LDH activities in medium and cell extract 
were calculated after volume correction. The percentage activity of LDH released from each culture was 
[LDHmedium/(LHDmedium+ LDHcells)]x 100%. The detection limit of the LDH assay was 5 U/L. Inter-assay 
variability was 12% at LDH activity of 110 U/L. The intra-assay variability was 3% and 6% at LDH 
activity of 110 U/L and 48 U/L, respectively. 
Troponin-I ELISA 
Purified human heart cTnI (Calbiochem, LaJolla, CA, USA) was dissolved in urea/Tris buffer according to 
the manufacturer’s instructions. Monoclonal mouse anti-cTnI clone 19C7 (recognizing amino acid 
residues (a.a.r.) 40-50) and monoclonal mouse anti-cTnI clone 6F9 (recognizing a.a.r. 189-195) were 
purchased from HyTest (Turku, Finland). The ELISA was based on the sandwich principle as described 
previously.9 The percentage cTnI released from each culture equalled [TnImedium/(TnImedium + 
TnIcells)]*100%. The detection limit of the assay was 6 μg/L. Inter-assay variability was 6% and 10%, 
at cTnI concentrations of 200 μg/L and 25 μg/L, respectively. The intra-assay variability was 6% at TnI 
concentration of 100 μg/L. 
Detection of troponin-I degradation products in autolytic myocardium 
and medium 
Testing the antibody 
The detection of intact cTnI and cTnI degradation products is antibody dependent.11, 12, 26 Therefore we 
tested whether cTnI degradation products in rat heart tissue undergoing ischemic autolysis could be 
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detected by a specific anti-cTnI antibody (clone K83085G, Biodesign, Saco, Maine, USA) recognizing 
a.a.r. 27-40. Hearts from anesthetized 2-day old Wistar male rats were rapidly dissected, and washed 
in a solution containing (in mmol/L) NaCl (137), KCl (5.4), Na2HPO4 (0.34), KH2PO4 (0.44), D-glucose 
(5.6), HEPES (20), and 0.02% Phenol Red, pH 7.4. Subsequently, ventricular myocardium (46 ± 7 mg 
tissue) was incubated for 0, 2, 4, 6, 8 and 10 h in a petri dish (∅ 1.5 cm) that was placed into another 
petri dish (∅ 3.5 cm) containing water at 37°C. After incubation, cardiac tissue was snap-frozen in 
liquid nitrogen, freeze-dried for at least 24 h, and homogenized in a buffer containing 0.1 mol/L Tris-
HCl and 0.1% (v/v) Tween-20 pH 7.5, using a Potter tube (Kimble/Kontes, Vineland, NJ, USA). 
Homogenates were stored in aliquots at -80°C. Protein concentrations were determined by bicinchonic 
acid (BCA) protein assay (Pierce, Etten-Leur, the Netherlands). In autolysing myocardium intact cTnI 
was detected by ELISA and Western blotting, and cTnI degradation products were detected by Western 
blotting. 
Western blotting 
Homogenates of heart tissue and medium samples of control and azide-treated cardiomyocyte cultures 
(10x concentrated by freeze-drying for 18 h) were size-fractionated on NuPage Novex 12% Bis-Tris gels 
(Invitrogen) and transferred to Hybond PVDF membranes (Amersham Biosciences, Roosendaal, The 
Netherlands). After blocking non-specific binding sites, membranes were incubated for 1 h with the 
anti-TnI antibody (K83085G, Biodesign), recognizing a.a.r. 27-40, and for 1 h with the horseradish 
peroxidase-labelled secondary antibody (rabbit anti-goat IgG, Santa Cruz Biotechnology, Heidelberg, 
Germany). Chemiluminescence was induced by ECL Advance Detection reagent (Amersham 
Biosciences) and detected by exposure to Hyperfilm ECL (Amersham Biosciences). 
Troponin-T assay 
cTnT concentrations in cell and medium samples of control and azide-treated cardiomyocytes were 
measured using the Elecsys 2010 (fourth-generation troponin-T test, Roche, Mannheim, Germany). 
Monoclonal human anti-cTnT clone M11.7 (recognizing a.a.r. 136-147) and monoclonal human anti-
cTnT clone M7 (recognizing a.a.r. 125-131) purchased from Hytest were used as capture and detection 
antibody, respectively. The detection limit for human cTnI in serum is 0.01 μg/L. The inter-assay 
variability was 8% and 7% at concentrations of 0.134 μg/L and 2.85 μg/L, respectively (n=89). 
Detection of troponin-T degradation products 
Intact cTnT and its degradation products in medium samples of control and azide-treated 
cardiomyocytes were detected by a novel immunoprecipitation assay.27, 28 Briefly, a mixture of four 
anti-cTnT antibodies (clones 9G6, 7F4, 7A9, and 1C11, a kind gift from Hytest) recognizing specific 
epitopes throughout the cTnT molecule were used to detect as many degradation products as possible. 
These antibodies were covalently immobilized on protein-A sepharose (GE Healthcare Europe, Diegem, 
Belgium) using dimethylpimelimidate (DMP, Sigma, Zwijndrecht, The Netherlands) as a cross-linking 
agent. Media of cardiomyocyte cultures were incubated with the sepharose beads to extract cTnT and 
its degradation products. Next, the beads were washed and incubated in sample buffer (40 mmol/L 
Tris, 33 g/L sodium dodecyl sulphate (SDS), 500 mL/L glycerol, and bromophenol blue). Samples were 
separated by SDS-PAGE on a Tris-HCl 4-15% polyacrylamide gradient gel (BioRad, Veenendaal, the 
Netherlands) and transferred to nitrocellulose (0.45 μm, BioRad) before incubation with a mixture of 
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the same monoclonal mouse anti-cTnT antibodies. A peroxidase-conjugated goat anti-mouse antibody 
(Dako, Glostrup, Denmark) was used for visualization by chemoluminescence (Perkin-Elmer Life 
Sciences, Waltham, MA, USA). Blots were captured on Kodak X-Omat blue film (Perkin-Elmer Life 
Sciences). 
Statistics 
Results are expressed as means ± SD. Statistical analysis was performed by Student´s t-test. 
Differences were regarded as statistically significant if p<0.05. SPSS14 for Windows (SPSS Inc, 
Chicago, IL, USA) was used for statistical analysis. 
RESULTS 
Detection of cardiac TnI degradation products in autolytic myocardium 
At baseline, the mean cTnI content in neonatal rat heart tissue was 0.72 μg/mg tissue (100%). After 10 
h of incubation, intact cTnI (29 kDa) was progressively reduced to ≈ 40% (Figure 6-1a and b), and 
three cTnI degradation products of 26, 24, 20 kDa were formed (Figure 6-1b). At baseline (t=0 h), a 
weak 26 kDa band was observed, being roughly 10 times smaller than the 29 kDa band (intact cTnI). 
This 26 kDa band represents a degradation product of cTnI. The intensity of this band increased during 
the first 4 h, followed by a decrease in the next 6 h of incubation, compatible with the formation and 
subsequent further degradation of a cTnI degradation product. 
 
Table 6-1. Total LDH, intact cTnI and cTnT per cardiomyocyte culture (cells+medium) treated with azide determined at 
t=0, 6, 12, 18, 24 and 30 h and expressed as percentage of activity or concentration present at t=0. 
Time (h) Total LDH (n=12) Total cTnI (n=9) Total cTnT (n=3) 
0 100  100 100 
6 95 ± 24 92 ± 21 105 ± 19 
12 96 ± 17 74 ± 12* 70 ± 6* 
18 97 ± 22  40 ± 26* 45 ± 19* 
24 86 ± 17* 34 ± 21* 39 ± 25* 
30 89 ± 19* 21 ± 7* 39 ± 28* 
* p<0.05 versus t=0 
LDH release during metabolic inhibition 
The mean LDH activity of 10 cultures at t=0 was 2.00 ± 0.43 U per culture. When incubated in HBSS, 
cardiomyocytes released ≈ 15% of total LDH in 30 h (Figure 6-2a), which confirms previous findings of 
cell death of cultured cardiomyocytes in serum-free medium.29 At times 0, 6 and 12 h, release of LDH 
from azide-treated cardiomyocytes equalled the LDH release of control cardiomyocytes, indicating no 
cardiomyocyte necrosis in the first 12 h. However, from 12 to 30 h, a prominent LDH release from 
azide-treated cardiomyocytes (up to 90% of total LDH) was demonstrated, indicating that necrotic cell 
death started after 12 h and was nearly complete at 30 h (Figure 6-2a). 
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Figure 6-1. (A) Degradation of intact cTnI in neonatal rat heart tissue undergoing autolysis for 0-10 h at 37°C, detected 
by ELISA. The mean cTnI content at t=0 (100%) was 0.72 μg/mg tissue. (B) Formation of cTnI degradation products in 
neonatal rat heart tissue undergoing autolysis for 0-10 h at 37°C, detected by Western blotting. Purified human heart 
cTnI was used as a positive control (POS). 
 
Release of cTnI during metabolic inhibition 
Intact cTnI assessed by ELISA. The mean content of intact cTnI in 10 cultures at t=0 was 1.2 ± 0.7 µg 
per culture. Control cardiomyocytes had released ≈ 9% of total cTnI after 30 h, which is most likely the 
result of cell death (≈15%) when incubated for 30 h in serum-free medium. The release of intact cTnI 
from azide-treated cardiomyocytes equalled that of control cardiomyocytes at time 0, 6 and 12 h, not 
exceeding 3%. At 18 h of azide treatment, cTnI release started to exceed control values (Figure 6-2b). 
At 30 h, cTnI release had increased to 51±16%, indicating a less abundant release of intact cTnI 
compared with the release of LDH. Secondly, during 12-30 h of azide treatment, the total amount of 
intact cTnI per culture was significantly reduced compared to that at t=0 (100%) (Table 6-1). 
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Figure 6-2. (A) Release of LDH (n=12), (b) release of intact cTnI (n=9), and (C) release of cTnT (n=3) from control and 
azide-treated (1 mmol/L) cardiomyocytes between 0 and 30 h. At t=0 (100%), the mean content of LDH, cTnI and cTnT 
was 2.00±0.34 U/culture, 1.2±0.7 μg/culture, and 0.23±0.08 μg/culture, respectively. Control cardiomyocytes are 
indicated by □ and azide-treated cardiomyocytes by ■. * p<0.05 versus control. 
 
cTnI degradation products assessed by western blotting 
To investigate whether a less abundant release of intact cTnI compared with that of LDH can be 
explained by the early formation of undetected cTnI degradation products, cTnI degradation products 
from control and azide-treated cardiomyocytes were studied by Western blotting (Figure 6-3a). In the 
first 12 h, only a relatively low quantity of intact cTnI was released that is consistent with the ELISA 
results. This intact cTnI is probably derived from the small proportion of necrotic cells (6-7%) in serum-
free medium, as this band is also observed in medium of control cardiomyocytes (Figure 6-3a). At 18 h, 
the intensity of intact cTnI (29 kDa) released from azide-treated cardiomyocytes had increased 
progressively and was accompanied by release of a 26 kDa band, indicating cTnI degradation (Figure 6-
3a). Enhanced degradation of cTnI was demonstrated at 24 and 30 h. In total four degradation 
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products of 26, 20, 17 and 12 kDa were detected in medium of azide-treated cardiomyocytes, and only 
after extensive cell death. In cell extracts of azide-treated cardiomyocytes, no degradation products of 
cTnI were detected during metabolic inhibition (data not shown). 
 
Figure 6-3. (A) Western blot of intact cTnI (29 kDa) and its degradation products in medium of control (LEFT) and 
azide-treated cardiomyocytes (right). (B) Western blot of intact cTnT (39 kDa) and its degradation products in medium 
of control (left) and azide-treated cardiomyocytes (right). 
Release of cTnT during metabolic inhibition 
cTnT assessed by immunoassay 
The mean content of cTnT in five cultures at t=0 was 0.23 ± 0.08 µg per culture. Control 
cardiomyocytes had released ≈ 16% of cTnT after 30 h in serum free-medium. The release of cTnT from 
azide-treated cardiomyocytes equalled that of control cardiomyocytes at 0, 6, and 12 h, not exceeding 
5%. At 18 h of azide treatment, cTnT release exceeded control values (Figure 6-2c). At 30 h, cTnT 
release had increased to 54±13%, which is comparable with the release of cTnI and less abundant 
compared to that of LDH. During 12-30 h of azide treatment also the total amount of cTnT per culture 
was significantly reduced compared with that at t=0 (100%)(Table 6-1). 
cTnT degradation products assessed by western blotting  
In medium of control cardiomyocytes no intact or degraded cTnT was detected between 0 and 30 h 
(Figure 6-3b). In medium of azide-treated cardiomyocytes, no intact or degraded cTnT was detected in 
the first 12 h, but at 18 h and later, release of intact cTnT (39 kDa) was observed and the intensity of 
this band increased after 24 and 30 h (Figure 6-3b). In total three cTnT degradation products of 37, 27, 
and 14 kDa were detected and only after extensive cell death. In cell extracts of azide-treated 
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cardiomyocytes, no degradation products of cTnT were observed during metabolic inhibition (data not 
shown). 
DISCUSSION 
The main findings of the present study are (1) release of cTnI or cTnT from energy-deprived 
cardiomyocytes does not occur before necrosis sets in, (2) cTnI and cTnT from necrotic cardiomyocytes 
are both released as intact protein and as degradation products, (3) the release kinetics of cTnI and 
cTnT from necrotic cardiomyocytes are comparable, and (4) the percentage release of troponins from 
necrotic cardiomyocytes remained lower than the percentage release of LDH. 
Myocardial ischemia causes extensive proteolytic damage to the myocardium and the plasma 
concentrations of cardiac proteins are used as biochemical markers of cardiac injury. Proteins released 
upon cardiac necrosis include LDH,25 α-hydroxybutyrate dehydrogenase (αHBDH),30 CK,31 the MB-
isoenzyme of CK (CK-MB),32 cTnI2 and cTnT,1 and these biochemical markers differ in sensitivity and 
specificity and vary in release kinetics.33, 34 LDH, αHBDH and CK are predominantly cytosolic proteins 
and not cardiac specific. Both troponins are highly cardiac specific and are bound, via tropomyosin, to 
actin filaments of sarcomeres, whereas only a small proportion of cTnT (6-8%) and cTnI (3-8%) is 
found in the soluble cytoplasmic pool.10 
Several studies have reported that the release of cTnI and cTnT in plasma of patients with AMI starts 
later than the release of CK-MB,5-8 suggesting that troponins are not ideal early markers for ruling out 
AMI. Vice versa, other studies have suggested that troponin release may also occur from reversibly 
damaged cardiomyocytes before necrosis sets in.20-22 Elevated troponin levels have been observed in 
patients without coronary syndromes who had normal CK-MBmass or CK-MBactivity levels,35, 36 indicating 
that under particular conditions circulating troponins may be present in the absence of necrotic 
cardiomyocyte death. 
The present study demonstrates that the first 12 h of mild metabolic inhibition did not cause necrosis. A 
sharp decline in cell viability was observed between 12 and 18 h and extensive cell death was 
demonstrated at 24 and 30 h. These results are consistent with a previous study of Chen et al., who 
defined the first 6-12 h of azide treatment (1 mmol/L) as a reversible phase, because wash-off 
experiments revealed that cardiomyocytes could regain full viability if azide was removed within the 
first 12 h. The reversible phase was followed by an irreversible phase (12-30 h) with progressive cell 
death.23 
Release of both intact and degraded cTnI or cTnT did not occur from reversibly damaged 
cardiomyocytes (0-12 h), but was associated with irreversible cell damage at t ≥ 18 h (Figs. 2 and 3). 
The release of intact cTnI and cTnT from necrotic cardiomyocytes was accompanied by the release of 
several degradation products (Figure 6-3). Four degradation products of cTnI (26, 20, 17 and 12kDa) 
and three degradation products of cTnT (37, 27 and 14 kDa) were observed when cardiomyocytes 
became irreversibly damaged. These results are in contrast with results reported by Kositprapa et al., 
who showed that metabolic inhibition of neonatal cardiomyocytes by azide treatment (1 mmol/L) 
caused degradation of cTnI in irreversibly damaged cardiomyocytes, whereas cTnT remained 
unaffected.37 The discrepancy between Kositprapa´s results and ours may be explained by the use of 
different cTnT antibodies. In the present study we used an immunoprecipitation method and western 
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blotting with several cTnT antibodies that recognized specified epitopes throughout the cTnT molecule 
to detect as many degradation products as possible, whereas Kositprapa et al. detected cTnT with only 
one cTnT antibody.37 
In the present study, release of intact cTnI and cTnT from irreversibly damaged cardiomyocytes showed 
similar kinetics (Figure 6-2b and Figure 6-2c). Nevertheless, the release of LDH from cardiomyocytes 
that become necrotic is more pronounced than the release of both troponins during 12-30 h azide-
treatment (Figure 6-2). The quantity of LDH released at 18 h was ≈60%, whereas the quantity of intact 
cTnI and cTnT was 18-28%. After 30 h, a maximal LDH release of ≈90% was associated with a cTnI and 
cTnT release of 50-55%, and these results confirmed our previous study.9 Although azide-treatment (1 
mmol/L) is less severe than metabolic inhibition induced by cyanide (5-10 mmol/L), 3 h of cyanide 
treatment resulted in a maximal LDH release (80-90%)9, 38 that was also associated with a cTnI release 
of ≈ 50%.9 
The mean content of total cTnI at t=0 was 1.2 ± 0.7 µg per culture, whereas the mean content of cTnT 
at t=0 was 0.23 ± 0.08 µg per culture. This difference might be explained by immunoassay 
characteristics. The fourth-generation cTnT assay has been developed and optimized for measurement 
of human cTnT and utilizes anti-human cTnT antibodies. Although rat cTnT is highly homologous to 
human cTnT, this might result in lower recoveries. In the cTnI ELISA, developed by our group,9 we used 
human anti-cTnI antibodies for the capture and detection of rat intact cTnI, but these antibodies 
demonstrated a comparable cross reactivity for rat cTnI compared with human cTnI. 
The cTnI ELISA that was used in the present study as well as in the previous study only detects full 
length cTnI (211 a.a.r.).9 Thus any cTnI degradation product that does not contain the two antigenic 
sites (a.a.r. 40-50 and a.a.r 198-195) will not be detected. Metabolic inhibition of cardiomyocytes 
induces the release of several degradation products of both cTnI and cTnT (Figure 6-3), which remained 
undetected by the immunoassays (Figure 6-2). During 12-30 h of azide treatment, total quantity of 
both intact cTnI and cTnT per culture (cells+medium) was significantly reduced compared with the total 
quantity at t=0 (100%), whereas total LDH activity was hardly reduced during azide treatment (Table 
1). These results indicate a loss of both intact cTnI and cTnT during metabolic inhibition. Degradation of 
intact troponins may be responsible for this reduction in total troponin per culture, as the immunoassay 
only detects intact troponin. However, troponin degradation products in medium of azide-treated 
cardiomyocytes detected by western blotting (Figure 6-3) may partially explain this reduction but do 
not explain a reduction by 60-80% (Table 1). In addition, there is no evidence for intracellular 
degradation of intact troponins, as degradation products were not observed in cell extracts of azide-
treated cardiomyocytes (data not shown). Therefore, these results suggest that also the antibodies 
used for western blotting may not be able to detect all troponin degradation products formed during 
metabolic inhibition. 
Undetected quantities of total intact cTnI and cTnT during azide treatment may be the result of post-
translational modifications of intact troponin. Post-translational modifications such as phosphorylation, 
oxidation or nitrosylation may result in an impaired binding capacity of the capture and/or detection 
antibody, leading to a reduced detection of intact troponin. 
The present study demonstrates that the detection of cardiac troponins depends on the formation of 
troponin degradation products and the immunoreactivity of the currently available antibodies for these 
degradation products. Released troponin degradation products may influence the result of the 
diagnostic assay. Whether the extent of irreversible cell damage after AMI is underestimated by the 
presence of troponin degradation products remains to be studied. Therefore further research is needed 
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to identify troponin degradation products in vivo and to develop methods to detect these fragments 
quantitatively. 
CONCLUSIONS 
Mild metabolic inhibition of neonatal rat cardiomyocytes induces parallel release of intact cTnI and cTnT 
and their degradation products, starting after onset of irreversible cardiomyocyte damage. 
In this study release kinetics of intact and degraded cTnI and cTnT were assessed by immunoassays 
and western blotting using currently available antibodies. If troponin degradation products do not 
contain the epitope for specific antibodies, they remain undetected. These limitations even apply to 
commercially available plasma troponin assays to be used for diagnosis of AMI. 
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CHAPTER 7 
THE DIAGNOSTIC VALUE OF SERUM AND URINARY NT-PROBNP 
FOR HEART FAILURE 
ABSTRACT 
Background. Serum B-type natriuretic peptide (BNP) and the amino-terminal cleavage product of the 
prohormone (NT-proBNP) have been shown to be valuable parameters for diagnosis of heart failure 
(HF) in the general population. Urinary BNP and NT-proBNP have also been suggested for diagnosis of 
HF. The present study investigated the diagnostic value of both serum and urinary NT-proBNP in 
selected groups of controls and patients diagnosed with HF. 
Methods. Creatinine clearance, and serum and urinary NT-proBNP were measured in 76 controls and in 
47 patients diagnosed with HF. Echocardiography was used to exclude cardiac dysfunction in the control 
population by the combined normality of left ventricular ejection fraction, e/a ratio, deceleration time, 
and left ventricular mass index. All patients diagnosed with HF had left ventricular ejection fractions 
<40%. 
Results. NT-proBNP measurements in urine samples are subject to high variability. Receiver operating 
characteristic area under the curve for serum, urinary NT-proBNP, and their product were 0.94, 0.72, 
and 0.93, respectively. Correction of urinary NT-proBNP for urinary creatinine content improved the 
area under the curve from 0.72 to 0.80. Negative predictive values for ruling out HF were 0.94, 0.67, 
and 0.89, respectively. Linear regression analysis revealed that creatinine clearance was more 
important in determining serum NT-proBNP levels than age. 
Conclusions. Serum NT-proBNP is the best parameter to rule out HF. The product of the serum and 
urinary NT-proBNP concentrations has equal value. In contrast, urinary NT-proBNP alone performs 
rather poorly. Renal function influences NT-proBNP levels more than age in this selected population. 
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INTRODUCTION 
Heart failure (HF) is a major public health problem of increasing relevance.1-3 It is important to realise 
that HF is the final stage of a variety of diseases affecting the heart. Hence, the population of HF 
patients is highly heterogeneous. Diagnosis of HF is based mainly on historical features (e.g. myocardial 
infarction), symptoms (e.g. dyspnoea), physical examination (e.g. third heart sound, leg oedema), 
chest radiography (e.g. interstitial oedema), and electrocardiography (e.g. atrial fibrillation).4 Additional 
laboratory analyses can include B-type natriuretic peptide (BNP) and the N-terminal cleavage product 
(NT-proBNP), which have become well established biochemical markers for diagnosis and prognosis of 
HF.5-8 
BNP (amino acid 77-108) and NT-proBNP (amino acid 1-76) are derived from proBNP (108 amino acids) 
by cleavage through the proteases furin,9 and corin.10 proBNP itself is derived from pre-proBNP (134 
amino acids) by cleavage of a signal peptide (26 amino acids).11, 12 Both peptides are released into the 
circulation from the cardiac ventricle in equimolar amounts. Release is induced by increased wall 
stretch, either mechanically or by volume overload.13 
NT-proBNP (8.5 kDa) is a low molecular weight peptide that is filtered by the glomerulus. It is unclear 
whether it has any biological activity. In contrast, the smaller and biologically active BNP (3.5 kDa) acts 
as an antagonist of the renin angiotensine aldosterone system, and protects the body from plasma 
overload by inducing diuresis, natriuresis, and vasodilatation.12 In addition to renal clearance, BNP is 
also cleared from the circulation through binding to natriuretic peptide receptor C (NPR-C). This 
complex is then internalised and BNP is enzymatically degraded. The receptor is externalised again to 
the outside of the cell membrane. The third mechanism involves neutral endopeptidase 24.11 (NEP), 
which also degrades circulating BNP.14, 15 Both mechanisms were shown to contribute equally to the 
clearance of BNP.16 These two additional mechanisms might explain the longer half life of NT-proBNP, 
compared with BNP.17 
Recently it was suggested to use the combined measurement of serum and urinary NT-proBNP in 
screening for left ventricular systolic dysfunction (LVSD) in the general population.18, 19 The aims of this 
study were to evaluate the Roche NT-proBNP immunoassay for measurement of urine samples and to 
investigate the diagnostic value of serum and urinary NT-proBNP in patients diagnosed with HF and in 
controls without cardiac abnormalities, as determined by stringent echocardiographic criteria. 
METHODS 
Study population 
This study was approved by the Medical Ethical Committee of the University Hospital Maastricht. All 
patients had echocardiography, blood sampling and 24 hours urine collection. The control group 
consisted of 76 patients who had no history of cardiac disease and were hospitalised for non-cardiac 
causes. Controls had normal echocardiography based on the following stringent and combined criteria: 
left ventricular ejection fraction (LVEF) >45%, e/a ratio >1.0 for patients <55 years and >0.8 for 
patients ≥55 years, deceleration time <220 ms, and left ventricular mass index (LVMI) ≤116 g/m2 in 
males and ≤104 g/m2 in females. In addition, 47 patients hospitalised for HF were recruited based on 
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diminished LVEF (<45%) as determined by echocardiographic examination of the heart. A total of 121 
serum and 89 urinary samples were analyzed. 
Laboratory analysis 
Serum samples were analysed for NT-proBNP and creatinine. Creatinine clearance and a 24-hour urine 
collection were used to estimate the glomerular filtration rate (GFR) as a parameter of renal function. 
NT-proBNP was measured on the Elecsys 2010 immunoassay system (Roche Diagnostics, Mannheim, 
Germany) with a sandwich immunoassay. The serum detection limit of the NT-proBNP immunoassay is 
0.6 pmol/L. Between-day variation is 2.4% and 2.2% at concentrations of 51.2 pmol/L and 800 pmol/L, 
respectively (n = 60). The reference values for the identification and exclusion of acute coronary heart 
failure were shown to be age dependent: 53 pmol/L (<50 years) and 106 pmol/L (> = 50 years).20, 21 
NT-proBNP concentrations are expressed in pmol/L, for conversion to pg/mL multiply by 8.457. 
Serum and urinary creatinine concentrations were measured on the Synchron LX-20 system (Beckman 
Coulter, Fullerton, USA) with the Jaffe method using alkaline picrate. Between-day variation of serum 
creatinine is 2.2% and 0.93% at concentrations of 86.9 µmol/L and 401 µmol/L, respectively (n = 93). 
The reference values are 71-110 µmol/L for men and 53-97 µmol/L for women. 
Urinary NT-proBNP 
Data on measurement of NT-proBNP in urine with the Roche immunoassay have not been published 
yet. Ng et al.18, 19 used an immunoluminometric assay (ILMA) with rabbit polyclonal antibodies for the 
detection of urinary NT-proBNP,22 whereas the Roche immunoassay utilises two sheep polyclonal 
antibodies recognising amino acid residues 10-21 and 39-50 of the molecule.  
Recombinant human NT-proBNP (rhNT-proBNP; 1-76) was kindly supplied by Roche (Mannheim, 
Germany) and was added to serum and urine samples, in which the NT-proBNP concentration was 
below the detection limit of the immunoassay. Concentrations were measured in the range 32-294 
pmol/L. Stability of NT-proBNP in urine was tested by measuring NT-proBNP during a 48 hour time span 
with aliquots of urine samples stored at different temperatures. The influence of urinary pH was tested 
by measuring urinary NT-proBNP before and after pH adjustment to a value of 7.4. 
Echocardiography 
One experienced cardiologist performed echocardiography for all subjects according to the standard 
clinical protocol used in our hospital. Data were collected on LVEF, LVSD, LV mass, LV mass index, and 
e/a ratio. The deceleration time was obtained from the electrocardiogram. 
Statistical analysis 
The Mann-Whitney U test was used for testing for differences between groups for continuous variables 
and the χ² test was used for categorical variables. The Spearman correlation coefficient (Rs) was used 
as a measure of correlation. The receiver operating characteristic (ROC) area under the curve (AUC) 
and the associated 95% confidence intervals were estimated. Optimal cut-off levels were calculated 
with combined highest sensitivity and specificity. Data are presented as medians with interquartile 
ranges (IQR) and P< 0.05 was considered statistically significant. The SPSS version 11.0.1 for Windows 
(SPSS, Chicago, USA) statistical software package was used for statistical analyses. 
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Table 7-1. Patient characteristics. 
 All (n=123) Control (n=76) HF (n=47) 
Men/ women 65 / 58 35 / 41 30 / 17 
Age, years 58 (21) 55 (20) 70 (18)* 
Creatinine clearance, ml/min 86 (81) 103 (46) 24 (37)* 
Serum NT-proBNP, pmol/L 18 (157) 6.9 (14) 359 (1408)* 
Serum creatinine, µmol/L 95 (87) 81 (37) 190 (185)* 
Urinary volume, ml/24h 1700 (900) 1755 (880) 1660 (1050)* 
Urinary creatinine, μmol/L 6.2 (4.3) 7.0 (5.1) 4.4 (4.0)* 
Urinary NT-proBNP, pmol/L 5.3 (21) 4.5 (4.0) 13 (515)* 
Urinary NT-proBNP, pmol/24h 6.9 (26) 5.1 (5.6) 26 (361)* 
Urinary NT-proBNP and creatinine quotient, pmol/μmol 0.75 (6.4) 0.41 (0.51) 5.2 (105)* 
Serum and urine NT-proBNP product, (pmol/L)2 106 (7954) 19 (33) 4776 (709977)* 
LVEF, % 61 (15) 64 (5) 42 (25)* 
LV mass, g 182 (77) 163 (39) 261 (137)* 
LV massindex, g/m2 91 (24) 87 (16) 139 (65)* 
E/A ratio 1.1 (0.5) 1.1 (0.45) 0.80 (0.73)† 
Deceleration time, ms 180 (210) 180 (38) 170 (120) 
Data are represented as median (interquartile range). The Mann-Whitney test was used for differences between controls 
and patients with HF. * p<0.0001; † p<0.05. 
RESULTS 
Assay feasibility 
Feasibility of the NT-proBNP immunoassay for the determination of urinary NT-proBNP was checked by 
addition of rhNT-proBNP to urine samples of different subjects. Figure 7-1 shows the standard curves 
for NT-proBNP measurements in two representative serum and urine samples using the Roche 
immunoassay in the range 32-293 pmol/L. In contrast to the 108% recovery found in serum samples, 
addition of rhNT-proBNP to urine resulted in lower recovery (16-55%). This was shown to be at least 
partly dependent on the urinary protein content of the sample (data not shown). The measurements 
were linear in the range tested. 
Storage of serum and urine samples at room temperature for up to 48 hours did not influence the 
concentration of NT-proBNP as measured by the Roche immunoassay. Urinary pH did not significantly 
influence NT-proBNP concentrations (after pH correction = 0.8267x - 2.5583; R2 = 0.994). 
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Urinary NT-proBNP 
Table 7-1 shows the characteristics of all subjects who participated in this study, 47 patients diagnosed 
with HF and 76 controls. HF patients and controls were not age matched (P<0.0001) and HF patients 
had lower creatinine clearance (P<0.0001). As expected, HF patients had significantly higher serum and 
urinary NT-proBNP values (P<0.0001). 
 
Table 7-2. Receiver operating characteristic area under the curve analysis for ruling out HF. 
 AUC 95% CI Cut-off Sensitivity Specificity PPV NPV 
Serum NT proBNP 
(pmol/L) 
0.940 0.884-0.996 33.5 91% 92% 88% 94% 
Urinary NT proBNP 
(pmol/L) 
0.721 0.610-0.831 10.5 53% 98% 96% 67% 
Serum and urinary NT 
proBNP product (pmol/L)2 
0.927 0.868-0.986 115 89% 93% 93% 89% 
Urinary NT proBNP and 
creatinine quotient 
(pmol/mmol) 
0.804 0.713-0.896 0.962 67% 86% 83% 72% 
AUC, Area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value. 
 
Figure 7-1. Standard curves for NT-proBNP measurement in serum and urine. rhNT-proBNP was spiked into two serum 
and two urine samples. The analytical response of the immunoassay was linear across the range from 32-294 pmol/L, 
independent of the matrix. 
 
In Figure 7-2 the relation between serum and urinary NT-proBNP is shown. There was a statistically 
significant correlation between urinary and serum NT-proBNP concentrations (Rs = 0.561, P<0.01). 
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Figure 7-3 shows the relation between serum and urinary NT-proBNP and age and creatinine clearance 
for both controls and patients diagnosed with HF. As calculated in the control population, serum NT-
proBNP increased significantly with age (Rs = 0.616, P<0.01), as did urinary NT-proBNP. The latter, 
however, with a lower correlation coefficient (Rs = 0.414, P<0.01). Serum NT-proBNP showed an 
inverse correlation with creatinine clearance (Rs = -0.777, P<0.01). Urinary NT-proBNP was also 
inversely correlated with creatinine clearance, but with a lower correlation coefficient (Rs = -0.524, 
P<0.01). 
 
Figure 7-2. Relation of serum and urinary NT-proBNP. Open circles represent controls and closed circles represent HF 
patients. Spearman correlation and 95% CI intervals were calculated with controls. 
 
Figure 7-4 shows the ROC curves for serum and urinary NT-proBNP, their product and the urinary NT-
proBNP corrected for urinary creatinine for diagnosis of HF. Table 7-2 shows the ROC AUC analysis for 
serum and urinary NT-proBNP for diagnosis of HF with corresponding sensitivity, specificity, and 
positive and negative predictive values. Serum NT-proBNP had the highest AUC (0.940) and urinary NT-
proBNP had the lowest (0.721). Correction for the urinary creatinine concentration increased the AUC to 
0.804. The sensitivity of urinary NT-proBNP was only 53%, but the specificity was 98%. Urinary NT-
proBNP had the highest PPV (96%) at a cut-off value of 10.5 pmol/L. Serum NT-proBNP had a 
sensitivity of 91%, a specificity of 92%, and a PPV of 88% at a concentration of 33.5 pmol/L. The 
serum and urinary NT-proBNP product performed equal to, but was not superior to serum NT-proBNP 
alone. 
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Figure 7-3. Serum and urinary NT-proBNP in relation to age and creatinine clearance. Open circles represent controls 
and closed circles represent HF patients. Spearman correlation and 95% CI intervals were calculated with controls. 
 
Figure 7-4. Receiver operating characteristic area under the curve for the detection of HF for serum NT-proBNP, urinary 
NT-proBNP, the product of both, and the urinary NT-proBNP corrected for urinary creatinine. 
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DISCUSSION 
Circulating BNP and NT-proBNP have been widely accepted and are now used by clinicians as 
biomarkers for assessing cardiac function.5-8 Several papers reported the use of plasma or serum NT-
proBNP measurements, but not urinary NT-proBNP measurements. Recent reports on the use of urinary 
NT-proBNP did not use the commercially available electrochemiluminescence immunoassay on the 
Elecsys 2010 platform that is marketed by Roche Diagnostics18, 19, except for one.23 The ILMA, originally 
evaluated with plasma samples was used for the detection of urinary NT-proBNP.22 Unfortunately, no 
details were provided on assay performance in urine samples. The first studies of this group reported 
that urinary NT-proBNP had diagnostic accuracy comparable with plasma NT-proBNP, and that urinary 
NT-proBNP may be suitable for diagnosis of HF.18 In the second study it was concluded that the most 
cost-effective strategy would be to apply these tests sequentially, using the urinary NT-proBNP test first 
to rule out LVSD and then subjecting the urine-positive cases to plasma testing.19 Cortés et al. reported 
good diagnostic value for urinary NT-proBNP for diagnosing HF with a ROC AUC value of 0.96±0.02 
(p<0.0001), compared with 0.98±0.01 for serum NT-proBNP. The conclusion was that urinary NT-
proBNP could be a simple non-invasive test for diagnosing HF. 
In the present study we evaluated the feasibility of the Roche NT-proBNP immunoassay for the 
determination of NT-proBNP in urine samples. First we investigated the stability of NT-proBNP in urine 
samples and found that samples were stable for up to 48 hours at room temperature. This is an 
important issue because patients have to collect 24 hours urine samples and it may take longer than 48 
hours before these samples can be analysed or frozen in the laboratory. When we analysed rhNT-
proBNP spiked in urine samples, the recoveries were rather low and varied substantially between 16-
55%. In contrast, serum samples had a mean recovery of 108% as determined within the same 
concentration range. The results in urine were, however, linear in the range 32-294 pmol/L. This might 
indicate an effect of the urine matrix, resulting in lower recovery, which might, at least partly, explain 
the lower diagnostic value of urinary NT-proBNP compared with serum NT-proBNP that was found. The 
analytical performance and diagnostic accuracy of this assay in serum samples have been evaluated 
elsewhere and these studies found excellent characteristics.24, 25 
Urinary NT-proBNP increased with increasing levels of serum NT-proBNP. This is to be expected 
because NT-proBNP is filtered by the kidneys. From Figure 7-2 it can be argued that there seems to be 
a threshold value of serum NT-proBNP of approximately 100 pmol/L before it starts to appear in urine. 
This phenomenon can be explained by limited renal resorption with increasing serum concentrations. 
The increase in serum NT-proBNP with decreasing renal function can be explained by diminished renal 
filtration. Impaired renal function, however, implies a lower filtering capacity of the kidneys. This is in 
contrast with the increasing urinary NT-proBNP when renal function becomes impaired. Possibly, NT-
proBNP is still small enough to be filtered, but this needs further investigation. 
We then investigated the diagnostic value of serum and urinary NT-proBNP for diagnosis of HF. The 
results from this study are in line with earlier studies that showed the effectiveness of serum NT-
proBNP for diagnosing HF in a variety of patient groups.5, 26-28  
In a recent study among 20,536 patients that measured NT-proBNP according to the method described 
by Karl et al.,29 NT-proBNP levels were strongly predictive for HF and other major vascular events.30 
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CONCLUSIONS 
The results from this study are in line with earlier data showing that serum NT-proBNP is most effective 
in ruling out HF. However, with the Roche NT-proBNP immunoassay, the use of urinary NT-proBNP did 
not show the high values reported by others.18, 19 Using serum NT-proBNP is the most easy to use 
method with least variability. We recommend the use of serum and not urine for measurements of NT-
proBNP for the diagnosis of heart failure. 
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CHAPTER 8 
GENERAL DISCUSSION 
TROPONINS IN CLINICAL PRACTISE 
Cardiac troponins were discovered in the late 1980’s and laboratory measurements of these proteins 
have since shown to be of great value for diagnosing myocardial cell damage and as such for diagnosis 
of acute coronary syndromes (ACS). Because of their cardiac tissue specificity, troponins have superior 
clinical value over the more classical enzyme measurements of myoglobin, CK, CK-MB or LDH (and its 
isoenzymes).1-3 In addition to their diagnostic value,4 troponins have also been shown to be of great 
value in risk stratification in patients with ACS,5, 6 end-stage renal disease (ESRD),7, 8 and patients with 
pulmonary embolism.9 In these and other studies,10-14 elevated troponin values were shown to be 
independent risk factors for a poor prognosis and higher risk of cardiac death. However, since there 
have been no internationally defined cut-off values for high and low risk patients, the troponins have 
not yet been fully integrated in risk stratification protocols. There have been many studies investigating 
multimarker strategies including the troponins and other cardiac markers such as myeloperoxidase 
(MPO), B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and C-
reactive protein (CRP) to determine the individual and combined values of these markers for risk 
stratification in patients presenting in the Emergency Department with chest pain or dyspnoea. The 
outcomes of these studies vary, depending on the study design and the numbers of patients included.15-
18 The number of elevated biomarkers of cardiac damage and function was shown to be an independent 
risk predictor for all-cause death.15, 16, 19 For example, in a cohort of 1635 patients Sabatine et al. 
showed that the number of elevated biomarkers (cTnI, CRP, and BNP) was a significant predictor of the 
composite endpoint after adjustment for known clinical predictors: patients with one, two, and three 
elevated biomarkers had a 2.1- (p=0.006), 3.1- (p<0.001), and 3.7- (p=0.001) fold increase in the 
composite risk of death, MI, or CHF by 6 months.19 In contrast, there has been one study reporting that 
the combination of cTnI with CK-MB or myoglobin was prognostically non-superior compared to cTnI 
alone.17 The causes of ACS include plaque rupture with acute thrombosis, progressive mechanical 
obstruction, inflammation, secondary unstable angina, and dynamic obstruction (coronary 
vasoconstriction).20 It is not surprising that a multi-marker strategy reflecting these underlying 
causes,19 including biomarkers for all these underlying causes - either cTnT or cTnI for myocardial 
damage combined with inflammation (CRP) and heart function (BNP/NT-proBNP) - is superior to a 
single marker strategy for risk stratification for all-cause-death or death from MI. This is also true for 
risk stratification for all-cause-death in patients with end stage renal disease.21 
Troponins can be measured in either serum or plasma samples and are rather stable at room 
temperature,3 Obviously, the time from blood sampling and pre analytical preparation to analysis, and 
the temperature is of influence on the outcome of the analysis.22 Use of heparin plasma samples has 
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been shown to result in approximately 6% lower cTnT and cTnI test results compared with serum.3, 23, 24 
This effect was elegantly shown to be caused by direct binding of heparin to the troponin molecule and 
could partly be reversed by the addition of heparinase or protamine.24 For the cTnT assay it was 
recently shown that the negative effect of heparin has been overcome.25 
Clinically it can be relevant to estimate infarct size. Troponins, being cardiac tissue specific, have been 
investigated as possible tools for this goal. Historically, infarct size has been estimated using serial and 
cumulative measurements of enzymes such as LDH, CK and CK-MBact.26-28 The troponins do not show 
the high correlations with anatomically (post-mortem) measured infarct sizes, or imaging techniques 
(e.g. thallium-201 scintigraphy) as the enzymatic estimations (cTnT r = 0.53, p = 0.042; CK-MBact r = 
0.64, p = 0.01).29 However, in several studies the opposite has been claimed, e.g. a single 
measurement of cTnT at 72 or 96 hours has been shown to correlate well with infarct size as estimated 
by thallium-201 scintigraphy (cTnT72: with reperfusion r=0.718; p<0.004, without reperfusion r=0.773; 
p<0.001),30 single-photon emission computed tomography (SPECT) using technetium-99 (cTnT72: 
r=0.62; p<0.001),31 magnetic resonance imaging (cTnT96: STEMI: r=0.910 and NSTEMI: r=0.575),32 or 
post mortem measurement of infarct size (cTnT96: r=0.74; p=0.001).33 Also, the cumulative troponin T 
release after 72 and after 168 hours correlated well with infarct size as estimated from cumulative 
enzyme release (r=0.82 and 0.84, respectively).34 And a more recent study showed that peak cTnT 
values correlated strongly to cumulative cTnT values (rs=0.97-0.98) as well as to DE-MRI (rs=0.8-
0.82), whereas clinical routine sampling showed lower rs values (0.47-0.60).35 In earlier studies we 
suggested that cTnT is only fractionally recovered after AMI.34 However, at that time we were not aware 
of fragmentation of cardiac troponin T. With the present insights, the partial recovery of cardiac 
troponin T can also be ascribed to degradation of cTnT as indicated in this thesis (Chapters 2, 3, 4, and 
6). 
Furthermore, troponins are measured via immunoassays and not enzymatically. Post translational 
modifications to troponin molecules36 and degradation as described in this thesis have major 
implications for current commercially available immunoassay performance, harmonization and 
standardization. It is currently unknown if these modifications have any clinical relevance, although 
disease specific forms have been demonstrated for cTnI.37, 38 
TROPONIN RELEASE AND CLEARANCE 
As a biochemical marker of myocardial cell death, cTnT is highly similar compared with cTnI. In the 
cardiomyocyte both are present in complexed form with troponin C and in small quantities (4-8%) as 
free molecules in the cytoplasm.39 Also, both are present in approximately equimolar amounts and are 
released after AMI in the same manner: they increase and reach peak levels parallel to each other, but 
cTnT tends to stay increased longer. This phenomenon is called the biphasic curve and this is seen in 
the majority of AMI patients with rapid reperfusion,40 unlike cTnI which always shows a monophasic 
release curve.22 Why these similar proteins have different release curves remains unclear. For cTnT it 
was originally suggested to be caused by the quick release of the small cytosolic (free) fraction and the 
slow release of the bound fraction.39 This is likely to be true because the troponin complex is bound 
tightly to tropomyosin via cTnT.41-43 It was shown that serial amino-terminal truncations of cTnT 
resulted in troponin complexes that were progressively smaller as judged by Stokes radius, and had a 
GENERAL DISCUSSION 
103 
progressive loss of ability to interact with tropomyosin and actin.42 It is possible that cTnT is released 
from the contractile apparatus more slowly than cTnI or TnC, which are not directly bound to 
tropomyosin. Another plausible explanation for both cTnT and cTnI could be related to the detection 
method (immunoassay) in combination with post translational protein modifications. These have been 
described for cTnI,38, 44 but also for cTnT.45 As described in Chapter 3, the patients studied also showed 
the typical biphasic serum release curve for cTnT. Most likely this originates from the disappearance of 
the intact molecule from the circulation and the presence of degradation products for longer periods. 
The presence of cTnT degradation products has been described in several studies,36, 46-50 but their 
presence has also been disputed.51-53 One study using perfused isolated rat hearts in a Langendorff 
setup showed with Western blot analysis using an antibody against cTnT, that cTnT was not degraded in 
the reperfusion effluent after 60 minutes of ischemia.54 This might indicate that cTnT is indeed released 
from ischemic cells in the intact form with degradation following in the circulation. The results from our 
studies (Chapter 3) are partly in line with these findings. We detected the intact protein in serum of 
three AMI patients within the first 12 hours after AMI. In some other patients fragments were already 
present in addition to the intact protein. However, more than 12 hours after AMI only fragments and no 
intact cTnT is present in the circulation. 
It is important to realize that there are several factors influencing the forms of a molecule present in 
the circulation.38 These include parameters that affect the quantity and forms of intracellular proteins 
(such as cTnT) present in blood such as disease-induced processing, post-translational modifications of 
the proteins inside the myocardium, as well as any further processing in the blood following the release 
from the myocardium. The time course of appearance for each protein (or its modified products) in the 
blood will depend on its molecular mass, its affinity for other proteins, and its localization in the cell.55, 
56 The disappearance from the circulation is influenced by other factors, including susceptibility to 
proteolysis and renal and lymphatic filtration. When using immunoassays for the detection of these 
proteins it is also important to include antibody affinity in this list. 
In this thesis (Chapter 6) we describe the appearance of cTnT and cTnI into culture medium of isolated 
rat neonatal cardiomyocytes after metabolic inhibition. Metabolic inhibition of rat neonatal 
cardiomyocytes results in reversible cell damage: after about 12 hours cells undergo a transition 
towards irreversible damage, as characterized by prominent DNA fragmentation, cell membrane 
leakage, mitochondrial dysfunction, and increased messenger RNA of the protease calpain.57 Because a 
cell culture is a closed system, there is no renal or lymphatic filtration, yet the total amount of both 
troponins decreased significantly over the 30 hour incubation period. In contrast, the amount of LDH 
remained constant. Western blot analysis revealed the presence of several degradation products of both 
cTnT and cTnI. From these combined experiments we concluded that troponins are released from the 
cardiomyocyte in both the intact, as well as in degraded form and that the available immunoassays do 
not measure all fragments. These results have major implications for the laboratory analysis of these 
proteins,58 and as such for the clinical interpretation of these parameters in a variety of diseases. 
IMPLICATIONS FOR ASSAY HARMONIZATION 
The main problem with cTnI is the plethora of assays available, utilizing different antibody combinations 
and calibrators. It is not surprising that these assays show a 20- to 40-fold difference between assays. 
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Results from one assay do therefore not necessarily apply to other cTnI assays or to the cTnT assay.22, 
59 Hence, it is important to evaluate the clinical implications of cTnI changes for each specific assay and 
confirm the prognostic value for the specific cTnI assay utilized at a particular laboratory. 
Harmonization of these assays is clearly needed. Towards this goal, the American Association of Clinical 
Chemistry (AACC) cTnI Standardization Committee collaborated with the National Institute of Standards 
and Technology (NIST) to select 2 candidate standard reference materials (SRM).58 The candidate that 
was shown to have most potential was SRM 2921, which according to the authors could assist in the 
harmonization once commutability was subsequently validated.60 In the Netherlands, a working group 
of the Dutch Foundation for Quality Assessment in Clinical Laboratories (SKML) recently investigated 
commutability of serum pools spiked with SRM 2921 and recombinant cTnI in a multi-centre survey by 
comparison of their behaviour to that of two patient serum pools (A and B) across several cTnI 
assays.61 Average recoveries of the SRM 2921-derived serum pool differed per cTnI method and ranged 
between 9-55%. Overall interlaboratory CVs for cTnI were above 50% in all tested pools. In case of 
patient pool A the overall interlaboratory CV for cTnI was 58%. With the candidates, i.e. using patient 
pool B, SRM 2921-based serum pool and the recombinant cTnI based serum pool as calibrators, 
theoretical interlaboratory CVs for patient pool A would have been 11%, 40% and 52%, respectively. 
When excluding one method with highest CV values, interlaboratory CVs for patient pool A were 13%, 
13% and 50%. These CV values illustrate that especially the patient pool, and to a lesser extent the 
SRM 2921 based pool, have potential for harmonization, whereas the pool spiked with recombinant cTnI 
has no potential for cTnI harmonization. The underlying cause for the low recoveries was not 
investigated. It is plausible this may be the result of degradation of the material in vitro caused by 
instability of the molecule itself, degradation by active proteases (calpain-1, caspase-3),62-66 or post 
translational modifications of the molecule.36, 38, 44 
Because there is only one manufacturer of cTnT immunoassays (Roche Diagnostics), regional or 
national harmonization of test results is not required. It is, however, important to realize that the 
degradation of cTnT as shown and discussed in Chapters 2, 3, 4 and 6 may very well have 
consequences. First, the use of a combination of two monoclonal antibodies automatically implies that 
some troponin fragments may not be measured. Clinically this does not have any consequences for the 
interpretation of the test result. All troponin immunoassays are valuable and validated assays that have 
proven to be of great value for the diagnosis and prognosis of ACS. Second, modification of the intact 
protein, to which these antibodies have been raised, may result in increased or decreased antibody 
binding to the molecule. Wu et al. have performed such experiments in vitro for cTnI and found 
remarkable differences in reactivity to various forms of cTnI that have been shown to be present in 
vivo.59 
FUTURE DIRECTIONS 
With the increased reliance of clinicians on cardiac troponins it is becoming more and more important 
for clinical chemists to realize exactly what is being measured with the current commercially available 
immunoassays. The work presented in this thesis was aimed at clarifying this issue for cTnT and 
answers therefore only partly the questions related to this issue. Future research will thus be aimed at 
clarifying the exact nature of the circulating cTnT fragments in a variety of diseases, such as AMI 
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patients, ESRD patients on hemodialysis or peritoneal dialysis and participants of prolonged exercise 
events. The hypothesis in these studies will be that there are disease specific forms of cTnT that are 
immunoreactive in the current immunoassay and therefore generate a positive test result. Maybe we 
can in the near future identify these disease specific degradation products and shed light on the often 
unexplained cTnT elevations seen in the above mentioned (and many other) conditions. It might also be 
of interest to develop a new cTnT immunoassay, specifically designed to detect the intact protein. 
Because this is only present in the first 13 hours after AMI, this will allow the distinction between a 
recent MI and more chronic cTnT elevations seen in for example ESRD patients. Unfortunately, there 
are legal aspects that prohibit the commercial development of such an assay, because of several 
patents owned by Roche Diagnostics. 
These studies will be performed using a combination of several techniques, including preparative SDS-
PAGE and tryptic digestion in combination with mass spectrometry to deduct from what part of the 
intact molecule the fragment originates. Furthermore, studies are now being performed in which 
antibody coated plates are used to extract cTnT from serum for measurement in immunocapture mass 
spectrometry and ellipsometry. Efforts are also underway to combine both cTnT and cTnI in all of the 
above mentioned experiments. 
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Cardiac troponins are proteins that facilitate muscle contraction. Together in a complex of three 
proteins (troponin T, I and C), they form the troponin complex. Troponin T binds the complex to 
tropomyosin, troponin I is the inhibiting part and troponin C binds the calcium ions that are needed for 
contraction. After binding of calcium the complex loses its natural inhibitory effect and allows the 
muscle to contract. There are two types of troponin I and T that are present in either skeletal muscle or 
heart muscle. The cardiac troponins I (cTnI) and T (cTnT) can be detected in the circulation with 
immunoassays that only react with the cardiac forms. They are the preferred biomarkers of cardiac 
tissue damage. It is rather difficult to study these proteins because cTnI and cTnT are not present in 
the circulation of healthy individuals. Only after cardiac tissue damage in for example acute coronary 
syndromes (ACS) the troponins will be released from the cardiac cells into the circulation, and 
depending on the severity of disease sometimes only in very small amounts. To overcome this issue, 
we developed and optimized a method for concentrating and purifying cTnT from serum from patients 
with troponin release (Chapter 2). With this method we extracted cTnT from patients with end stage 
renal disease who were on hemodialysis. The different molecular forms of cTnT were separated based 
on their molecular weight with gel electrophoresis (SDS-PAGE). We showed the presence of cTnT 
fragments, but not the intact protein in these patients, who at that time did not have clinically 
diagnosed cardiac tissue damage or ACS. Importantly, these patients did have positive cTnT 
concentrations. 
We then investigated the release of cTnT in patients with an acute myocardial infarction (AMI). We 
looked at the release of cTnT after onset of symptoms with the method described in Chapter 2 and 
investigated the molecular forms of cTnT at different times after AMI (Chapter 3). We showed for the 
first time that the circulating forms of cTnT are dependent on the time after onset of symptoms. The 
intact protein is only present in the first 12 hours and thereafter only fragments are present. The 
current immunoassay detects both the intact form and (several) degraded cTnT forms. Importantly, 
from in vitro experiments it became clear that the absolute concentration is influenced by 
fragmentation (Chapter 4). One issue that we could not overcome in these experiments was the 
availability of the original antibodies that are used in the commercial immunoassay. We therefore 
utilized size-exclusion chromatography, a different technique for separation of proteins based on size, 
and used the current immunoassay to detect cTnT (Chapter 4). In vitro studies showed rapid 
degradation of the intact protein and the appearance of smaller forms that reacted positively in the 
immunoassay. Analysis of serum from patients with AMI confirmed the presence of smaller circulating 
forms of cTnT in these patients as was demonstrated in Chapter 3. 
Elevations of cTnT after strenuous and prolonged endurance events (marathon, triathlon) have been 
reported. It remains, however, difficult to determine whether these elevations are the result of 
reversible or irreversible damage to the heart. When we reviewed the available literature (Chapter 5) 
we found that 59% of all participants in these events had detectable cTnT levels within 1 hour after the 
race that decreased within 24 to 48 hours. This percentage is dependent on the immunoassay 
generation and the cut-off values for cTnT that were used. Most studies showed that these effects were 
transient, suggesting that the release of cTnT represents reversible cardiac damage. 
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It is unknown in what form the cardiac troponins are released into the circulation. We therefore looked 
in more detail to the release of cTnI and cTnT from the cardiac cell using neonatal rat cardiomyocytes, 
a model of metabolically induced ischemia (Chapter 6). We showed parallel release of intact cTnI, cTnT 
and their degradation products starting directly after onset of irreversible cardiomyocyte damage. There 
was hardly any troponin release during the reversible phase of the metabolic inhibition, although the 
total cTnT and cTnI concentrations per culture (cells + medium) decreased during the first 12 hours. 
Troponin release after 30 hours was only a fraction of the release of Lactate Dehydrogenase activity 
(LDH). There was progressive loss of cTnI and cTnT that was undetected by the antibodies used and 
already occurred during the first 12 hours, possibly due to degradation of troponin. In a separate study 
we investigated the value of a biomarker of heart function and volume overload, serum amino terminal-
proBNP (NT-proBNP) for ruling out heart failure (HF). We describe that renal function influences NT-
proBNP levels more than age in this selected population and demonstrate that serum NT-proBNP is the 
best predictor of HF (Chapter 7). The product of the serum and urinary NT-proBNP concentrations has 
equal value, but urinary NT-proBNP alone has a lower diagnostic accuracy. The above mentioned issues 
are discussed in the light of the most recent literature and insights of the present time in the final 
chapter, which also states directions for future research (Chapter 8). 
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Cardiale troponines zijn eiwitten die betrokken zijn bij spiercontractie. Samen, in een complex van drie 
eiwitten (troponine T, I en C), vormen ze het troponine complex. Troponine T bindt het complex aan 
tropomyosine, troponine I is het remmende (inhiberende) deel van het complex en troponine C bindt de 
calcium ionen die nodig zijn voor spiercontractie. Nadat een calcium ion gebonden is door het troponine 
complex, verliest troponine I zijn van nature remmende werking en de spier trekt samen. Er bestaan 
twee vormen van troponine I en T die vóórkomen in of skeletweefsel, of hartspierweefsel. De cardiale 
troponines I (cTnI) en T (cTnT) kunnen in de bloedsomloop gedetecteerd worden met immunoassays 
die alleen reageren met de cardiale vormen. De cardiale troponines zijn de meest specifieke biomerkers 
van hartspierschade. Het is vrij lastig om deze eiwitten te bestuderen omdat cTnI en cTnT niet 
voorkomen in de bloedsomloop van gezonde individuen. Alleen na hartspierschade, bijvoorbeeld zoals 
optreedt na een acuut myocard infarct (AMI), komen de troponines vrij uit de hartspiercellen waarna ze 
in de bloedsomloop terecht komen. Afhankelijk van de ernst van het AMI soms slechts in lage 
concentraties. Om dit probleem van biologische beschikbaarheid te omzeilen hebben we een methode 
ontwikkeld en geoptimaliseerd waarmee we cTnT uit serum van patiënten met troponine verhogingen 
kunnen zuiveren en concentreren (Hoofdstuk 2). Met behulp van deze methode extraheerden we cTnT 
uit serum van patiënten met eind stadium nierfalen die hiervoor werden gehemodialyseerd. De 
verschillende moleculaire vormen van cTnT werden gescheiden op grootte (molecuul gewicht) met 
gelelectrophorese (SDS-PAGE). Wij toonden de aanwezigheid van fragmenten van cTnT aan, maar 
konden het intacte eiwit niet aantonen in deze patiënten (die op dat moment geen klinisch te 
diagnosticeren hartspierschade of AMI hadden). Het is belangrijk om te realiseren dat deze patiënten 
desondanks positieve cTnT concentraties hadden. Vervolgens onderzochten we het vrijkomen van cTnT 
in patiënten met AMI. Door wederom gebruik te maken van de methode beschreven in Hoofdstuk 2 
bestudeerden we het vrijkomen na aanvang van de symptomen (Hoofdstuk 3). We lieten voor het eerst 
zien dat de circulerende vormen van cTnT in de bloedsomloop afhankelijk zijn van het tijdstip na 
aanvang van de symptomen. Het intacte eiwit is alleen in de eerste 12 uur aantoonbaar en daarna zijn 
alleen nog maar fragmenten aantoonbaar. De huidige immunoassay detecteert zowel het intacte eiwit 
en (enkele) fragmenten of gedegradeerde cTnT vormen. Uit in vitro experimenten werd duidelijk dat de 
absolute cTnT concentratie zoals gemeten met de huidige immunoassay beïnvloed wordt door 
fragmentatie (Hoofdstuk 4). Helaas hadden we in alle voorgaande experimenten niet de beschikking 
over de antilichamen die in de commerciële immunoassay gebruikt worden. Hierdoor was het 
onmogelijk om de gevonden fragmenten te koppelen aan de kwantitatieve uitslagen van de 
immunoassay. We hebben daarom gebruik gemaakt van size-exclusion chromatografie, een andere 
techniek om eiwitten op grootte te scheiden, en gebruikten de commerciële immunoassay om cTnT te 
detecteren (Hoofdstuk 4). In vitro studies lieten een snelle degradatie van het intacte eiwit zien met 
tegelijkertijd het verschijnen van kleinere cTnT vormen die positief resultaat gaven in de immunoassay. 
Analyse van serum van patiënten met AMI bevestigde de aanwezigheid van kleine circulerende vormen 
van cTnT in deze patients zoals met een andere techniek was aangetoond in het onderzoek beschreven 
in Hoofdstuk 3. Verhogingen van cTnT na extreme en langdurige inspanning (marathon, triathlon) zijn 
eerder beschreven. Het blijft echter moeilijk om vast te stellen of deze verhogingen het resultaat zijn 
van reversibele or irreversibele schade aan het hart. We hebben de beschikbare literatuur op een rijtje 
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gezet (Hoofdstuk 5) en vonden dat 59% van alle deelnemers aan deze evenementen detecteerbare 
cTnT concentraties hadden binnen 1 uur na de race die afnamen binnen 24 tot 48 uur. Dit percentage is 
afhenkelijk van de generatie van de immunoassay die werd gebruikt en de afkapwaarden die voor cTnT 
werden gehanteerd. De meeste studies toonden aan data deze effecten reversibel waren en suggereren 
vervolgens dat het vrijkomen van cTnT in de bloedsomloop reversibele hartspierschade representeert. 
Het is onbekend in welke vormen de cardiale troponines in de bloedsomloop worden vrijgemaakt. 
Daarom bestudeerden we in meer detail door gebruik te maken van neonatale ratten hartspiercellen. 
Dit is een model voor ischemie door het celmetabolisme stil te leggen (Hoofdstuk 6). Het bleek dat 
intact cTnI, cTnT en hun degradatieproducten direct vrijkomen nadat de cellen de overgang doormaken 
van reversibele naar irreversibele schade. Tijdens de reversibele fase kwam er nauwelijks troponine uit 
de cellen, terwijl de totale hoeveelheid troponine in de cel en het medium waarin ze gekweekt werden 
afnam in de eerste 12 uur. De hoeveelheid troponine die na 30 uur vrijgekomen was uit de cellen was 
slechts een fractie van de Lactaat Dehydrogenase activiteit (LDH). Er was progressief verlies van beide 
troponines in de eerste 12 uur die niet werd gemeten met de door ons gebruikte antilichamen. Mogelijk 
is de verklaring hiervoor degradatie van de intacte moleculen waardoor antilichamen niet meer kunnen 
binden. In een aparte studie onderzochten we de diagnostische waarde van een biomarker voor 
hartfunctie en overvulling, serum amino terminaal-proBNP (NT-proBNP) voor het uitsluiten van 
hartfalen (HF). We vonden dat nierfunctie een grotere invloed heeft op de NT-proBNP concentratie dan 
leeftijd in de door ons onderzochte populatie en toonden aan dat serum NT-proBNP de beste voorspeller 
is voor de aanwezigheid van (Hoofdstuk 7). Het product van de serum en urine NT-proBNP 
concentraties heeft dezelfde disagnostische waarde, maar de urine NT-proBNP concentratie alleen heeft 
een lagere diagnostische waarde. De bovengenoemde zaken worden bediscussieerd tegen het licht van 
de meest recente literatuur en inzichten van vandaag in het laatste hoofdstuk (Hoofstuk 8). Tevens 
worden hierin mogelijkheden van vervolgonderzoek besproken. 
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